1
|
Gos M, Cebula J, Goszczyński TM. Metallacarboranes in Medicinal Chemistry: Current Advances and Future Perspectives. J Med Chem 2024; 67:8481-8501. [PMID: 38769934 DOI: 10.1021/acs.jmedchem.4c00157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/22/2024]
Abstract
Metallacarboranes, exemplified by cobalt bis(dicarbollide) ([COSAN]-), have excelled their historical metallocene analogue label to become promising in drug design, medical studies, and fundamental biological research. Serving as a unique platform for conjugation with biomolecules, they also constitute an auspicious building block for biologically active derivatives and a carrier for cellular transport of membrane-impermeable cargos. Modified [COSAN]- exhibits specific antimicrobial, antiviral, and anticancer actions showing promise for preclinical trials. Contributing to the ongoing development in medicinal chemistry, metallacarboranes offer desirable physicochemical properties and low acute toxicity. This article presents a critical look at metallacarboranes in the context of their application in medicinal chemistry, emphasizing [COSAN]- as a potential game-changer in drug design and biomedical sciences. As medicinal chemistry seeks innovative building blocks, metallacarboranes emerge as an important novelty with versatile solutions and promising implications.
Collapse
Affiliation(s)
- Michalina Gos
- Laboratory of Biomedical Chemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, Poland
| | - Jakub Cebula
- Laboratory of Biomedical Chemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, Poland
| | - Tomasz M Goszczyński
- Laboratory of Biomedical Chemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, Poland
| |
Collapse
|
2
|
Fujikawa Y, Kawabata S, Tsujino K, Yamada H, Kashiwagi H, Yagi R, Hiramatsu R, Nonoguchi N, Takami T, Sasaki A, Hu N, Takata T, Tanaka H, Suzuki M, Wanibuchi M. Boron neutron capture therapy delays the decline in neurological function in a mouse model of metastatic spinal tumors. Cancer Sci 2024. [PMID: 38860412 DOI: 10.1111/cas.16245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2024] [Revised: 05/16/2024] [Accepted: 05/31/2024] [Indexed: 06/12/2024] Open
Abstract
Metastatic spinal tumors are increasingly prevalent due to advancements in cancer treatment, leading to prolonged survival rates. This rising prevalence highlights the need for developing more effective therapeutic approaches to address this malignancy. Boron neutron capture therapy (BNCT) offers a promising solution by delivering targeted doses to tumors while minimizing damage to normal tissue. In this study, we evaluated the efficacy and safety of BNCT as a potential therapeutic option for spine metastases in mouse models induced by A549 human lung adenocarcinoma cells. The animal models were randomly allocated into three groups: untreated (n = 10), neutron irradiation only (n = 9), and BNCT (n = 10). Each mouse was administered 4-borono-L-phenylalanine (250 mg/kg) intravenously, followed by measurement of boron concentrations 2.5 h later. Overall survival, neurological function of the hindlimb, and any adverse events were assessed post irradiation. The tumor-to-normal spinal cord and blood boron concentration ratios were 3.6 and 2.9, respectively, with no significant difference observed between the normal and compressed spinal cord tissues. The BNCT group exhibited significantly prolonged survival rates compared with the other groups (vs. untreated, p = 0.0015; vs. neutron-only, p = 0.0104, log-rank test). Furthermore, the BNCT group demonstrated preserved neurological function relative to the other groups (vs. untreated, p = 0.0004; vs. neutron-only, p = 0.0051, multivariate analysis of variance). No adverse events were observed post irradiation. These findings indicate that BNCT holds promise as a novel treatment modality for metastatic spinal tumors.
Collapse
Affiliation(s)
- Yoshiki Fujikawa
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Shinji Kawabata
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Kohei Tsujino
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Hironori Yamada
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Hideki Kashiwagi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Ryokichi Yagi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Ryo Hiramatsu
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Naosuke Nonoguchi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Toshihiro Takami
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Akinori Sasaki
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan
| | - Masahiko Wanibuchi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka, Japan
| |
Collapse
|
3
|
Kondo N, Kinouchi T, Natsumeda M, Matsuzaki J, Hirata E, Sakurai Y, Okada M, Suzuki M. Profile of miRNAs in small extracellular vesicles released from glioblastoma cells treated by boron neutron capture therapy. J Neurooncol 2024; 168:91-97. [PMID: 38598087 DOI: 10.1007/s11060-024-04649-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2024] [Accepted: 03/14/2024] [Indexed: 04/11/2024]
Abstract
PURPOSE Boron neutron capture therapy (BNCT) is a tumor cell-selective particle-radiation therapy. In BNCT, administered p-boronophenylalanine (BPA) is selectively taken up by tumor cells, and the tumor is irradiated with thermal neutrons. High-LET α-particles and recoil 7Li, which have a path length of 5-9 μm, are generated by the capture reaction between 10B and thermal neutrons and selectively kill tumor cells that have uptaken 10B. Although BNCT has prolonged the survival time of malignant glioma patients, recurrences are still to be resolved. miRNAs, that are encapsulated in small extracellular vesicles (sEVs) in body fluids and exist stably may serve critical role in recurrence. In this study, we comprehensively investigated microRNAs (miRNAs) in sEVs released from post-BNCT glioblastoma cells. METHOD Glioblastoma U87 MG cells were treated with 25 ppm of BPA in the culture media and irradiated with thermal neutrons. After irradiation, they were plated into dishes and cultured for 3 days in the 5% CO2 incubator. Then, sEVs released into the medium were collected by column chromatography, and miRNAs in sEVs were comprehensively investigated using microarrays. RESULT An increase in 20 individual miRNAs (ratio > 2) and a decrease in 2 individual miRNAs (ratio < 0.5) were detected in BNCT cells compared with non-irradiated cells. Among detected miRNAs, 20 miRNAs were associated with worse prognosis of glioma in Kaplan Meier Survival Analysis of overall survival in TCGA. CONCLUSION These miRNA after BNCT may proceed tumors, modulate radiation resistance, or inhibit invasion and affect the prognosis of glioma.
Collapse
Affiliation(s)
- Natsuko Kondo
- Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-Nishi, Kumatori, Sennan-gun, Osaka, 590-0494, Japan.
| | - Tadatoshi Kinouchi
- Division of Radiation Biochemistry, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-Nishi, Kumatori, Sennan-gun, Osaka, 590-0494, Japan
| | - Manabu Natsumeda
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
| | - Juntaro Matsuzaki
- Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan
| | - Eishu Hirata
- Division of Tumor Cell Biology and Bioimaging, Cancer Research Institute of Kanazawa University, Kanazawa, Japan
| | - Yoshinori Sakurai
- Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-Nishi, Kumatori, Sennan-gun, Osaka, 590-0494, Japan
| | - Masayasu Okada
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
| | - Minoru Suzuki
- Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-Nishi, Kumatori, Sennan-gun, Osaka, 590-0494, Japan
| |
Collapse
|
4
|
Taskaeva I, Kasatova A, Razumov I, Bgatova N, Taskaev S. Lithium salts cytotoxicity and accumulation in melanoma cells in vitro. J Appl Toxicol 2024; 44:712-719. [PMID: 38146629 DOI: 10.1002/jat.4576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Revised: 11/29/2023] [Accepted: 12/13/2023] [Indexed: 12/27/2023]
Abstract
Boron neutron capture therapy is a perspective selective technology for the destruction of cancer cells, while the use of lithium instead of boron may represent a new and promising vector for the development of neutron capture therapy (NCT). The aim of the study was a comparative assessment of the cytotoxicity of various lithium salts, as well as an analysis of the accumulation of lithium in tumor cells in vitro to determine the possibility of using lithium in NCT. The cytotoxicity of lithium salts was determined using MTT-test and colony forming assay on human fibroblasts BJ-5ta, human skin melanoma SK-Mel-28, and mouse skin melanoma B16 cell lines. An assessment of lithium concentration in cells was performed using inductively coupled plasma atomic emission spectrometry. Our results showed that three different lithium salts at a concentration of 40 μg/ml are not toxic for both tumor and normal cells. The highest uptake values were obtained on murine melanoma B16 cells when exposed to lithium carbonate (0.8 μg/106 cells); however, human melanoma SK-Mel-28 cells effectively accumulated both lithium carbonate and lithium citrate (about 0.46 μg/106 cells for two salts). Thus, our results demonstrate a range of non-toxic doses of lithium salts and a high uptake of lithium by tumor cells, which indicates the possibility to use the lithium in NCT.
Collapse
Affiliation(s)
- Iuliia Taskaeva
- Laboratory of Ultrastructural Research, Research Institute of Clinical and Experimental Lymphology-Branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
- Budker Institute of Nuclear Physics, Novosibirsk, Russia
| | - Anna Kasatova
- Budker Institute of Nuclear Physics, Novosibirsk, Russia
| | - Ivan Razumov
- Center for Genetic Resources of Laboratory Animals, Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | - Nataliya Bgatova
- Laboratory of Ultrastructural Research, Research Institute of Clinical and Experimental Lymphology-Branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | - Sergey Taskaev
- Budker Institute of Nuclear Physics, Novosibirsk, Russia
| |
Collapse
|
5
|
Wróblewska A, Szermer-Olearnik B, Szczygieł A, Węgierek-Ciura K, Mierzejewska J, Kozień D, Żeliszewska P, Kruszakin R, Migdał P, Pędzich Z, Pajtasz-Piasecka E. Macrophages as carriers of boron carbide nanoparticles dedicated to boron neutron capture therapy. J Nanobiotechnology 2024; 22:183. [PMID: 38622691 PMCID: PMC11017526 DOI: 10.1186/s12951-024-02397-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Accepted: 03/18/2024] [Indexed: 04/17/2024] Open
Abstract
BACKGROUND The use of cells as carriers for the delivery of nanoparticles is a promising approach in anticancer therapy, mainly due to their natural properties, such as biocompatibility and non-immunogenicity. Cellular carriers prevent the rapid degradation of nanoparticles, improve their distribution, reduce cytotoxicity and ensure selective delivery to the tumor microenvironment. Therefore, we propose the use of phagocytic cells as boron carbide nanoparticle carriers for boron delivery to the tumor microenvironment in boron neutron capture therapy. RESULTS Macrophages originating from cell lines and bone marrow showed a greater ability to interact with boron carbide (B4C) than dendritic cells, especially the preparation containing larger nanoparticles (B4C 2). Consequently, B4C 2 caused greater toxicity and induced the secretion of pro-inflammatory cytokines by these cells. However, migration assays demonstrated that macrophages loaded with B4C 1 migrated more efficiently than with B4C 2. Therefore, smaller nanoparticles (B4C 1) with lower toxicity but similar ability to activate macrophages proved to be more attractive. CONCLUSIONS Macrophages could be promising cellular carriers for boron carbide nanoparticle delivery, especially B4C 1 to the tumor microenvironment and thus prospective use in boron neutron capture therapy.
Collapse
Affiliation(s)
- Anna Wróblewska
- Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, Wrocław, 53-114, Poland.
| | - Bożena Szermer-Olearnik
- Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, Wrocław, 53-114, Poland
| | - Agnieszka Szczygieł
- Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, Wrocław, 53-114, Poland
| | - Katarzyna Węgierek-Ciura
- Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, Wrocław, 53-114, Poland
| | - Jagoda Mierzejewska
- Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, Wrocław, 53-114, Poland
| | - Dawid Kozień
- Faculty of Materials Science and Ceramics, Department of Ceramics and Refractory Materials, AGH University of Krakow, Krakow, Poland
| | - Paulina Żeliszewska
- Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Kracow, Poland
| | - Roksana Kruszakin
- Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, Wrocław, 53-114, Poland
| | - Paweł Migdał
- Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, Wrocław, 53-114, Poland
| | - Zbigniew Pędzich
- Faculty of Materials Science and Ceramics, Department of Ceramics and Refractory Materials, AGH University of Krakow, Krakow, Poland
| | - Elżbieta Pajtasz-Piasecka
- Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, Wrocław, 53-114, Poland
| |
Collapse
|
6
|
Chen J, Li Y, Gan X, Weng C, Fang X, Liu G. Unlocking the potential: phenylboronic acid as a nuclear-targeting boron agent for neutron capture therapy. Med Oncol 2024; 41:104. [PMID: 38573420 DOI: 10.1007/s12032-024-02351-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Accepted: 03/04/2024] [Indexed: 04/05/2024]
Abstract
It has been proposed that boron neutron capture therapy (BNCT) holds promise as a treatment modality for melanoma. However, the effectiveness of boron agents in delivery remains a critical issue to be addressed for BNCT. To this end, phenylboronic acid, which exhibits good water solubility and low cytotoxicity similar to BPA, has been investigated as a potential nuclear-targeting boron agent. The boron concentration of phenylboronic acid was found to be 74.47 ± 12.17 ng/106 B16F10 cells and 45.77 ± 5.64 ng/106 cells in the nuclei. Molecular docking experiments were conducted to investigate the binding of phenylboronic acid to importin proteins involved in nuclear transport. The potential of phenylboronic acid to serve as a desirable nucleus-delivery boron agent for neutron capture therapy in melanoma warrants further exploration.
Collapse
Affiliation(s)
- Jiejian Chen
- Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, Guangdong, China
| | - Yonghao Li
- Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, Guangdong, China
| | - Xiaoning Gan
- Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, Guangdong, China
| | - Chengyin Weng
- Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, Guangdong, China
| | - Xisheng Fang
- Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, Guangdong, China
| | - Guolong Liu
- Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, Guangdong, China.
| |
Collapse
|
7
|
Taskaeva YS, Kasatova AI, Shatruk AY, Taskaev SY, Bgatova NP. The Expression of Markers of Acute Kidney Injury Kim1 and NGAL after Administration of High Doses of Lithium Carbonate in Mice with Engrafted Skin Melanoma B16. Bull Exp Biol Med 2024; 176:567-571. [PMID: 38724809 DOI: 10.1007/s10517-024-06068-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Indexed: 05/18/2024]
Abstract
The expression of marker proteins of acute kidney injury after administration of high doses of lithium carbonate was assessed to evaluate the possibility of lithium use in neutron capture therapy. In mice with implanted skin melanoma B16, the expression of Kim1 (kidney injury molecule 1) and NGAL (neutrophil gelatinase-associated lipocalin) proteins in the kidneys was evaluated immunohistochemically 15, 30, 90, 180 min, and 7 days after peroral administration of lithium carbonate at single doses of 300 and 400 mg/kg. An increase in the expression of the studied proteins was found in 30 and 90 min after administration of 400 mg/kg lithium carbonate, however, 7 days after the drug administration, the expression returned to the level observed in the control group. It can be suggested that single administration of lithium carbonate in the studied doses effective for lithium neutron capture therapy will not significantly affect the renal function.
Collapse
Affiliation(s)
- Yu S Taskaeva
- Research Institute of Clinical and Experimental Lymphology - Branch of Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.
- Budker Institute of Nuclear Physics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.
| | - A I Kasatova
- Budker Institute of Nuclear Physics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | - A Yu Shatruk
- Research Institute of Clinical and Experimental Lymphology - Branch of Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | - S Yu Taskaev
- Budker Institute of Nuclear Physics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | - N P Bgatova
- Research Institute of Clinical and Experimental Lymphology - Branch of Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
| |
Collapse
|
8
|
Caracciolo A, Ferri T, Borghi G, Carminati M, Protti N, Altieri S, Fiorini C. A compact scintillator-based detector with collimator and shielding for dose monitoring in boron neutron capture therapy. Phys Imaging Radiat Oncol 2024; 29:100556. [PMID: 38405430 PMCID: PMC10891326 DOI: 10.1016/j.phro.2024.100556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Revised: 02/06/2024] [Accepted: 02/08/2024] [Indexed: 02/27/2024] Open
Abstract
Boron neutron capture therapy exploits 10B(n,α )7Li reactions for targeted tumor destruction. In this work, we aimed at developing a dose monitoring system based on the detection of 478 keV gamma rays emitted by the reactions, which is very challenging due to the severe background present. We investigated a compact gamma-ray detector with a pinhole collimator and shielding housing. Experimental nuclear reactor measurements involved varying boron concentrations and artificial shifts of the sources. The system successfully resolved the 478 keV photopeak and detected 1 cm lateral displacements, confirming its suitability for precise boron dose monitoring.
Collapse
Affiliation(s)
- Anita Caracciolo
- Dipartimento di Elettronica, Informazione and Bioingegneria, Politecnico di Milano, Milano 20133, Italy
- Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Milano, Milano 20133, Italy
| | - Tommaso Ferri
- Dipartimento di Elettronica, Informazione and Bioingegneria, Politecnico di Milano, Milano 20133, Italy
- Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Milano, Milano 20133, Italy
| | - Giacomo Borghi
- Dipartimento di Elettronica, Informazione and Bioingegneria, Politecnico di Milano, Milano 20133, Italy
- Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Milano, Milano 20133, Italy
| | - Marco Carminati
- Dipartimento di Elettronica, Informazione and Bioingegneria, Politecnico di Milano, Milano 20133, Italy
- Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Milano, Milano 20133, Italy
| | - Nicoletta Protti
- Dipartimento di Fisica, Università di Pavia, Pavia 27100, Italy
- Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Pavia 27100, Italy
| | - Saverio Altieri
- Dipartimento di Fisica, Università di Pavia, Pavia 27100, Italy
- Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Pavia 27100, Italy
| | - Carlo Fiorini
- Dipartimento di Elettronica, Informazione and Bioingegneria, Politecnico di Milano, Milano 20133, Italy
- Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Milano, Milano 20133, Italy
| |
Collapse
|
9
|
Zavestovskaya IN, Kasatova AI, Kasatov DA, Babkova JS, Zelepukin IV, Kuzmina KS, Tikhonowski GV, Pastukhov AI, Aiyyzhy KO, Barmina EV, Popov AA, Razumov IA, Zavjalov EL, Grigoryeva MS, Klimentov SM, Ryabov VA, Deyev SM, Taskaev SY, Kabashin AV. Laser-Synthesized Elemental Boron Nanoparticles for Efficient Boron Neutron Capture Therapy. Int J Mol Sci 2023; 24:17088. [PMID: 38069412 PMCID: PMC10707216 DOI: 10.3390/ijms242317088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 11/23/2023] [Accepted: 11/27/2023] [Indexed: 12/18/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is one of the most appealing radiotherapy modalities, whose localization can be further improved by the employment of boron-containing nanoformulations, but the fabrication of biologically friendly, water-dispersible nanoparticles (NPs) with high boron content and favorable physicochemical characteristics still presents a great challenge. Here, we explore the use of elemental boron (B) NPs (BNPs) fabricated using the methods of pulsed laser ablation in liquids as sensitizers of BNCT. Depending on the conditions of laser-ablative synthesis, the used NPs were amorphous (a-BNPs) or partially crystallized (pc-BNPs) with a mean size of 20 nm or 50 nm, respectively. Both types of BNPs were functionalized with polyethylene glycol polymer to improve colloidal stability and biocompatibility. The NPs did not initiate any toxicity effects up to concentrations of 500 µg/mL, based on the results of MTT and clonogenic assay tests. The cells with BNPs incubated at a 10B concentration of 40 µg/mL were then irradiated with a thermal neutron beam for 30 min. We found that the presence of BNPs led to a radical enhancement in cancer cell death, namely a drop in colony forming capacity of SW-620 cells down to 12.6% and 1.6% for a-BNPs and pc-BNPs, respectively, while the relevant colony-forming capacity for U87 cells dropped down to 17%. The effect of cell irradiation by neutron beam uniquely was negligible under these conditions. Finally, to estimate the dose and regimes of irradiation for future BNCT in vivo tests, we studied the biodistribution of boron under intratumoral administration of BNPs in immunodeficient SCID mice and recorded excellent retention of boron in tumors. The obtained data unambiguously evidenced the effect of a neutron therapy enhancement, which can be attributed to efficient BNP-mediated generation of α-particles.
Collapse
Affiliation(s)
- Irina N. Zavestovskaya
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991, Russia; (M.S.G.); (V.A.R.)
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Moscow 115409, Russia (I.V.Z.); (G.V.T.); (A.A.P.); (S.M.K.); (S.M.D.)
| | - Anna I. Kasatova
- Laboratory of BNCT, Budker Institute of Nuclear Physics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia; (A.I.K.); (D.A.K.); (K.S.K.); (S.Y.T.)
| | - Dmitry A. Kasatov
- Laboratory of BNCT, Budker Institute of Nuclear Physics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia; (A.I.K.); (D.A.K.); (K.S.K.); (S.Y.T.)
| | - Julia S. Babkova
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Moscow 115409, Russia (I.V.Z.); (G.V.T.); (A.A.P.); (S.M.K.); (S.M.D.)
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow 117997, Russia
| | - Ivan V. Zelepukin
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Moscow 115409, Russia (I.V.Z.); (G.V.T.); (A.A.P.); (S.M.K.); (S.M.D.)
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow 117997, Russia
| | - Ksenya S. Kuzmina
- Laboratory of BNCT, Budker Institute of Nuclear Physics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia; (A.I.K.); (D.A.K.); (K.S.K.); (S.Y.T.)
| | - Gleb V. Tikhonowski
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Moscow 115409, Russia (I.V.Z.); (G.V.T.); (A.A.P.); (S.M.K.); (S.M.D.)
| | - Andrei I. Pastukhov
- LP3, Aix-Marseille University, CNRS, 13288 Marseille, France; (A.I.P.); (A.V.K.)
| | - Kuder O. Aiyyzhy
- A. M. Prokhorov General Physics Institute of the Russian Academy of Sciences, Moscow 119991, Russia; (K.O.A.); (E.V.B.)
| | - Ekaterina V. Barmina
- A. M. Prokhorov General Physics Institute of the Russian Academy of Sciences, Moscow 119991, Russia; (K.O.A.); (E.V.B.)
| | - Anton A. Popov
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Moscow 115409, Russia (I.V.Z.); (G.V.T.); (A.A.P.); (S.M.K.); (S.M.D.)
| | - Ivan A. Razumov
- Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia; (I.A.R.); (E.L.Z.)
| | - Evgenii L. Zavjalov
- Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia; (I.A.R.); (E.L.Z.)
| | - Maria S. Grigoryeva
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991, Russia; (M.S.G.); (V.A.R.)
| | - Sergey M. Klimentov
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Moscow 115409, Russia (I.V.Z.); (G.V.T.); (A.A.P.); (S.M.K.); (S.M.D.)
| | - Vladimir A. Ryabov
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991, Russia; (M.S.G.); (V.A.R.)
| | - Sergey M. Deyev
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Moscow 115409, Russia (I.V.Z.); (G.V.T.); (A.A.P.); (S.M.K.); (S.M.D.)
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow 117997, Russia
- Laboratory of Molecular Pharmacology, Institute of Molecular Theranostics, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia
- “Biomarker” Research Laboratory, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia
| | - Sergey Yu. Taskaev
- Laboratory of BNCT, Budker Institute of Nuclear Physics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia; (A.I.K.); (D.A.K.); (K.S.K.); (S.Y.T.)
| | - Andrei V. Kabashin
- LP3, Aix-Marseille University, CNRS, 13288 Marseille, France; (A.I.P.); (A.V.K.)
| |
Collapse
|
10
|
Raitano A, Martin T, Zhang C, Malinao MC, Capo L, Ikeura M, Carroll R, Quintana JC, Dlamini S, Kulenovic L, Jahanshir E, Kang S, Morrison K, Torgov M, Morrison K. Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Re-emerging Boron Neutron Capture Therapy Field. J Med Chem 2023; 66:13809-13820. [PMID: 37729617 DOI: 10.1021/acs.jmedchem.3c01265] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/22/2023]
Abstract
Boron neutron capture therapy (BNCT) is a re-emerging binary cellular level cancer intervention that occurs through the interaction of a cancer-specific 10boron (10B) drug and neutrons. We created a new 10B drug, 3-borono-l-tyrosine (BTS), that improves on the characteristics of the main historical BNCT drug 4-borono-l-phenylalanine (BPA). BTS has up to 4 times greater uptake in vitro than BPA and increased cellular retention. Like BPA, BTS uptake is mediated by the l-type amino acid transporter-1 (LAT1) but is less sensitive to natural amino acid competition. BTS can be formulated and bolus dosed at much higher levels than BPA, resulting in 2-3 times greater boron delivery in vivo. Fast blood clearance and greater tumor boron delivery result in superior tumor-to-blood ratios. BTS boron delivery appears to correlate with LAT1 expression. BTS is a promising boron delivery drug that has the potential to improve modern BNCT interventions.
Collapse
Affiliation(s)
- Arthur Raitano
- Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States
| | - Tioga Martin
- Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States
| | - Chunying Zhang
- Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States
| | - Maria-Christina Malinao
- Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States
| | - Linnette Capo
- Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States
| | - Maki Ikeura
- Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States
| | - Rebecca Carroll
- Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States
| | - Jason C Quintana
- Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States
| | - Samkeliso Dlamini
- Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States
| | - Leila Kulenovic
- Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States
| | - Eva Jahanshir
- Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States
| | - Sohye Kang
- Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States
| | - Karen Morrison
- Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States
| | - Michael Torgov
- Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States
| | - Kendall Morrison
- Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States
| |
Collapse
|
11
|
Cui PF, Liu XR, Jin GX. Supramolecular Architectures Bearing Half-Sandwich Iridium- or Rhodium-Based Carboranes: Design, Synthesis, and Applications. J Am Chem Soc 2023; 145:19440-19457. [PMID: 37643971 DOI: 10.1021/jacs.3c05563] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/31/2023]
Abstract
The utilization of carboranes in supramolecular chemistry has attracted considerable attention. The unique spatial configuration and weak interaction forces of carboranes can help to explore the properties of supramolecular complexes, particularly via host-guest chemistry. Additionally, certain difficulties encountered in carborane development─such as controlled B-H bond activation─can be overcome by judiciously selecting metal centers and their adjacent ligands. However, few studies are being conducted in this nascent research area. With advances in this field, novel carborane-based supramolecular complexes will likely be prepared, structurally characterized, and intrinsically investigated. To expedite these efforts, we present major findings from recent studies, including π-π interactions, host-guest associations, and steric effects, which have been leveraged to implement a regioselective process for activating B(2,9)-, B(2,8)-, and B(2,7)-H bonds of para-carboranes and B(4,7)-H bonds of ortho-carboranes. Future studies should clarify the unique weak interactions of carboranes and their potential for enhancing the utility of supramolecular complexes. Although carboranes exhibit several unique weak interactions (such as dihydrogen-bond [Bδ+-Hδ-···Hδ+-Cδ-], Bδ+-Hδ-···M+, and Bδ+-Hδ-···π interactions), the manner in which they can be utilized remains unclear. Supramolecular complexes, particularly those based on host-guest chemistry, can be utilized as a platform for demonstrating potential applications of these weak interactions. Owing to the importance of alkane separation, applications related to the recognition and separation of alkane isomers via dihydrogen-bond interactions are primarily summarized. Advances in the research of unique weak interactions in carboranes will certainly lead to more possibilities for supramolecular chemistry.
Collapse
Affiliation(s)
- Peng-Fei Cui
- State Key Laboratory of Molecular Engineering of Polymers, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Department of Chemistry, Fudan University, 2005 Songhu Road, Shanghai, 200433, People's Republic of China
| | - Xin-Ran Liu
- State Key Laboratory of Molecular Engineering of Polymers, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Department of Chemistry, Fudan University, 2005 Songhu Road, Shanghai, 200433, People's Republic of China
| | - Guo-Xin Jin
- State Key Laboratory of Molecular Engineering of Polymers, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Department of Chemistry, Fudan University, 2005 Songhu Road, Shanghai, 200433, People's Republic of China
| |
Collapse
|
12
|
Coghi P, Li J, Hosmane NS, Zhu Y. Next generation of boron neutron capture therapy (BNCT) agents for cancer treatment. Med Res Rev 2023; 43:1809-1830. [PMID: 37102375 DOI: 10.1002/med.21964] [Citation(s) in RCA: 14] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Revised: 03/27/2023] [Accepted: 04/12/2023] [Indexed: 04/28/2023]
Abstract
Boron neutron capture therapy (BNCT) is one of the most promising treatments among neutron capture therapies due to its long-term clinical application and unequivocally obtained success during clinical trials. Boron drug and neutron play an equivalent crucial role in BNCT. Nevertheless, current clinically used l-boronophenylalanine (BPA) and sodium borocaptate (BSH) suffer from large uptake dose and low blood to tumor selectivity, and that initiated overwhelm screening of next generation of BNCT agents. Various boron agents, such as small molecules and macro/nano-vehicles, have been explored with better success. In this featured article, different types of agents are rationally analyzed and compared, and the feasible targets are shared to present a perspective view for the future of BNCT in cancer treatment. This review aims at summarizing the current knowledge of a variety of boron compounds, reported recently, for the application of BCNT.
Collapse
Affiliation(s)
- Paolo Coghi
- School of Pharmacy, Macau University of Science and Technology, Macau, China
| | - Jinxin Li
- School of Pharmacy, Macau University of Science and Technology, Macau, China
| | - Narayan S Hosmane
- Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, Illinois, USA
| | | |
Collapse
|
13
|
Zhang Y, Kang HG, Xu HZ, Luo H, Suzuki M, Lan Q, Chen X, Komatsu N, Zhao L. Tumor Eradication by Boron Neutron Capture Therapy with 10 B-enriched Hexagonal Boron Nitride Nanoparticles Grafted with Poly(Glycerol). ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2023; 35:e2301479. [PMID: 37243974 DOI: 10.1002/adma.202301479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 05/08/2023] [Indexed: 05/29/2023]
Abstract
Boron neutron capture therapy (BNCT) has emerged as a treatment modality with high precision and efficacy of intractable tumors. At the core of effective tumor BNCT are 10 B carriers with facile preparation as well as advantageous pharmacokinetic and therapeutic profiles. Herein, the design and preparation of sub-10 nm 10 B-enriched hexagonal boron nitride nanoparticles grafted with poly(glycerol) (h-10 BN-PG), and their application to cancer treatment by BNCT are reported. By virtue of their small particle size and outstanding stealth property, h-10 BN-PG nanoparticles accumulate efficiently in murine CT26 colon tumors with a high intratumor 10 B concentration of 8.8%ID g-1 or 102.1 µg g-1 at 12 h post-injection. Moreover, h-10 BN-PG nanoparticles penetrate into the inside of the tumor parenchyma and then are taken up by the tumor cells. BNCT comprising a single bolus injection of h-10 BN-PG nanoparticles and subsequent one-time neutron irradiation results in significant shrinkage of subcutaneous CT26 tumors. h-10 BN-PG-mediated BNCT not only causes direct DNA damage to the tumor cells, but also triggers pronounced inflammatory immune response in the tumor tissues, which contributes to long-lasting tumor suppression after the neutron irradiation. Thus, the h-10 BN-PG nanoparticles are promising BNCT agents to eradicate tumor through highly efficient 10 B accumulation.
Collapse
Affiliation(s)
- Yucai Zhang
- State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, Jiangsu, 215123, China
| | - Heon Gyu Kang
- Graduate School of Human and Environmental Studies, Kyoto University, Sakyo-ku, Kyoto, 606-8501, Japan
| | - Hua-Zhen Xu
- Department of Pharmacology, School of Basic Medical Sciences, Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Donghu Avenue No.185, Wuhan, 430072, China
| | - Honghui Luo
- State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, Jiangsu, 215123, China
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka, 590-0494, Japan
| | - Qing Lan
- Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China
| | - Xiao Chen
- Department of Pharmacology, School of Basic Medical Sciences, Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Donghu Avenue No.185, Wuhan, 430072, China
| | - Naoki Komatsu
- Graduate School of Human and Environmental Studies, Kyoto University, Sakyo-ku, Kyoto, 606-8501, Japan
| | - Li Zhao
- State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, Jiangsu, 215123, China
| |
Collapse
|
14
|
Shanmugam M, Kuthala N, Kong X, Chiang CS, Hwang KC. Combined Gadolinium and Boron Neutron Capture Therapies for Eradication of Head-and-Neck Tumor Using Gd 10B 6 Nanoparticles under MRI/CT Image Guidance. JACS AU 2023; 3:2192-2205. [PMID: 37654578 PMCID: PMC10466345 DOI: 10.1021/jacsau.3c00250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 07/16/2023] [Accepted: 07/26/2023] [Indexed: 09/02/2023]
Abstract
Eradication of head-and-neck (H&N) tumors is very difficult and challenging because of the characteristic feature of frequent recurrence and the difficulty in killing cancer stem cells. Neutron capture therapy (NCT) is emerging as a noninvasive potential modality for treatments of various types of tumors. Herein, we report that 98.5% 10B-enriched anti-EGFR-Gd10B6 nanoparticles can not only deliver large doses of 158 μg 10B/g tumor tissues as well as 56.8 μg 157Gd/g tumor tissues with a very high tumor-to-blood (T/B) 10B ratio of 4.18, but also exert very effective CT/MRI image-guided combined GdBNCT effects on killing cancer stem cells and eradication of recurrent head-and-neck (H&N) tumors. This leads to a long average half-lifespan of 81 days for H&N tumor-bearing mice, which is a record-making result, and surpasses the best result reported in the literature using combined radiotherapy and T cell-mediated immunotherapy (70 d).
Collapse
Affiliation(s)
- Munusamy Shanmugam
- Department
of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan ROC
| | - Naresh Kuthala
- Department
of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan ROC
| | - Xiangyi Kong
- Department
of Breast Surgical Oncology, National Cancer Center/National Clinical
Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Chi-Shiun Chiang
- Department
of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan R.O.C.
| | - Kuo Chu Hwang
- Department
of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan ROC
| |
Collapse
|
15
|
Monti Hughes A, Hu N. Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies. Cancers (Basel) 2023; 15:4091. [PMID: 37627119 PMCID: PMC10452654 DOI: 10.3390/cancers15164091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 07/27/2023] [Accepted: 07/31/2023] [Indexed: 08/27/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a tumor-selective particle radiotherapy. It combines preferential boron accumulation in tumors and neutron irradiation. The recent initiation of BNCT clinical trials employing hospital-based accelerators rather than nuclear reactors as the neutron source will conceivably pave the way for new and more numerous clinical trials, leading up to much-needed randomized trials. In this context, it would be interesting to consider the implementation of new boron compounds and strategies that will significantly optimize BNCT. With this aim in mind, we analyzed, in this review, those articles published between 2020 and 2023 reporting new boron compounds and strategies that were proved therapeutically useful in in vitro and/or in vivo radiobiological studies, a critical step for translation to a clinical setting. We also explored new pathologies that could potentially be treated with BNCT and newly developed theranostic boron agents. All these radiobiological advances intend to solve those limitations and questions that arise during patient treatment in the clinical field, with BNCT and other therapies. In this sense, active communication between clinicians, radiobiologists, and all disciplines will improve BNCT for cancer patients, in a cost- and time-effective way.
Collapse
Affiliation(s)
- Andrea Monti Hughes
- Radiation Pathology Division, Department Radiobiology, National Atomic Energy Commission, San Martín, Buenos Aires B1650KNA, Argentina
- National Scientific and Technical Research Council, Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan;
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka 590-0494, Japan
| |
Collapse
|
16
|
Ye M, Li B, Shi W, Liu H, Wang Y, Chen W, Wang J, Wang G. Preparation and tumor-targeting evaluation of BS-CyP albumin nanoparticles modified with hyaluronic acid based on boron neutron capture therapy. J Biomed Mater Res A 2023; 111:1176-1184. [PMID: 36740897 DOI: 10.1002/jbm.a.37506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 01/03/2023] [Accepted: 01/13/2023] [Indexed: 02/07/2023]
Abstract
Radiation therapy has been widely used in the clinical treatment of tumors. Due to the low radiation absorption of tumors, a high dose of ionizing radiation is often required during radiotherapy, which causes serious damage to normal tissues near tumors. Boron neutron capture therapy (BNCT) is more targeted than conventional radiotherapy. To improve the therapeutic effect of cancer, albumin was selected as the drug carrier to wrap the fluorescent tracer boron drug BS-CyP and prepare the nanoparticles. Then, we developed a novel tumor-targeting nano-boron drug by using hyaluronic acid to modify the nanoparticles. We found that BS-CyP albumin nanoparticles modified with hyaluronic acid effectively delayed drug release and enhanced the aggregation, in tumors, showing good safety with no obvious toxicity to cells and mice. This study confirmed the advantages of boron drugs modified with hyaluronic acid targeting tumors and may provide a reference for BNCT.
Collapse
Affiliation(s)
- Minjun Ye
- Key Laboratory of Biorheological and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Modern Life Science Experiment Teaching Center at Bioengineering College of Chongqing University, Chongqing, China
| | - Bingyi Li
- Key Laboratory of Biorheological and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Modern Life Science Experiment Teaching Center at Bioengineering College of Chongqing University, Chongqing, China
| | - Wanyu Shi
- International Department, Nankai Middle School, Chongqing, China
| | - Huaize Liu
- International Department, Nankai Middle School, Chongqing, China
| | - Yi Wang
- Key Laboratory of Biorheological and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Modern Life Science Experiment Teaching Center at Bioengineering College of Chongqing University, Chongqing, China
| | - Weiqing Chen
- Gastroenterology Oncology Department, Affiliated Cancer Hospital of Chongqing University, Chongqing, China
| | - Jian Wang
- Executive Management, Chongqing Gaojin Biological Company, Chongqing, China
| | - Guixue Wang
- Key Laboratory of Biorheological and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Modern Life Science Experiment Teaching Center at Bioengineering College of Chongqing University, Chongqing, China
| |
Collapse
|
17
|
Yamana K, Kawasaki R, Kondo K, Hirano H, Kawamura S, Sanada Y, Bando K, Tabata A, Azuma H, Takata T, Sakurai Y, Tanaka H, Kodama T, Kawamoto S, Nagasaki T, Ikeda A. HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/β-1,3-glucan complex. NANOSCALE ADVANCES 2023; 5:3857-3861. [PMID: 37496630 PMCID: PMC10367957 DOI: 10.1039/d3na00028a] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Accepted: 05/23/2023] [Indexed: 07/28/2023]
Abstract
The development of boron agents with integrated functionality, including biocompatibility, high boron content, and cancer cell targeting, is desired to exploit the therapeutic efficacy of boron neutron capture therapy (BNCT). Here, we report the therapeutic efficacy of BNCT using a HER-2-targeted antibody-conjugated boron nitride nanotube/β-1,3-glucan complex. The anticancer effect of BNCT using our system was 30-fold that of the clinically available boron agent l-BPA/fructose complex.
Collapse
Affiliation(s)
- Keita Yamana
- Program of Applied Chemistry, Graduate School of Advanced Science and Engineering 1-4-1 Kagamiyama Higashi-Hiroshima City 739-8527 Japan
| | - Riku Kawasaki
- Program of Applied Chemistry, Graduate School of Advanced Science and Engineering 1-4-1 Kagamiyama Higashi-Hiroshima City 739-8527 Japan
| | - Kousuke Kondo
- Program of Applied Chemistry, Graduate School of Advanced Science and Engineering 1-4-1 Kagamiyama Higashi-Hiroshima City 739-8527 Japan
| | - Hidetoshi Hirano
- Program of Applied Chemistry, Graduate School of Advanced Science and Engineering 1-4-1 Kagamiyama Higashi-Hiroshima City 739-8527 Japan
| | - Shogo Kawamura
- Program of Applied Chemistry, Graduate School of Advanced Science and Engineering 1-4-1 Kagamiyama Higashi-Hiroshima City 739-8527 Japan
| | - Yu Sanada
- Institute for Integrated Radiation and Nuclear Science, Kyoto University 2, Asahiro-Nishi, Kumatori-cho, Sennan-gun Osaka 590-0494 Japan
| | - Kaori Bando
- Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka Metropolitan University 3-3-138 Sugimoto, Sumiyoshi-ku Osaka City 558-8585 Japan
| | - Anri Tabata
- Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka Metropolitan University 3-3-138 Sugimoto, Sumiyoshi-ku Osaka City 558-8585 Japan
| | - Hideki Azuma
- Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka Metropolitan University 3-3-138 Sugimoto, Sumiyoshi-ku Osaka City 558-8585 Japan
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University 2, Asahiro-Nishi, Kumatori-cho, Sennan-gun Osaka 590-0494 Japan
| | - Yoshinori Sakurai
- Institute for Integrated Radiation and Nuclear Science, Kyoto University 2, Asahiro-Nishi, Kumatori-cho, Sennan-gun Osaka 590-0494 Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University 2, Asahiro-Nishi, Kumatori-cho, Sennan-gun Osaka 590-0494 Japan
| | - Tomoki Kodama
- Program of Biotechnology, Graduate School of Integrated Sciences for Life, Hiroshima University 1-3-1 Kagamiyama Higashi-Hiroshima 739-8530 Japan
| | - Seiji Kawamoto
- Program of Biotechnology, Graduate School of Integrated Sciences for Life, Hiroshima University 1-3-1 Kagamiyama Higashi-Hiroshima 739-8530 Japan
| | - Takeshi Nagasaki
- Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka Metropolitan University 3-3-138 Sugimoto, Sumiyoshi-ku Osaka City 558-8585 Japan
| | - Atsushi Ikeda
- Program of Applied Chemistry, Graduate School of Advanced Science and Engineering 1-4-1 Kagamiyama Higashi-Hiroshima City 739-8527 Japan
| |
Collapse
|
18
|
Balcer E, Sobiech M, Giebułtowicz J, Sochacka M, Luliński P. Molecularly Imprinted Polymers Specific towards 4-Borono-L-phenylalanine-Synthesis Optimization, Theoretical Analysis, Morphology Investigation, Cytotoxicity, and Release Studies. Polymers (Basel) 2023; 15:3149. [PMID: 37514538 PMCID: PMC10386447 DOI: 10.3390/polym15143149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 07/17/2023] [Accepted: 07/21/2023] [Indexed: 07/30/2023] Open
Abstract
The aim of this study was to create molecularly imprinted polymers (MIPs) that are specific towards 4-borono-L-phenylalanine (BPA) to serve as boron compound carriers. The honeycomb-like MIPs were characterized in the matter of adsorption properties, morphology, structure, and cytotoxicity towards A549 and V79-4 cell lines. The honeycomb-like MIP composed from methacrylic acid and ethylene glycol dimethacrylate was characterized by a binding capacity of 330.4 ± 4.6 ng g-1 and an imprinting factor of 2.04, and its ordered, porous morphology was confirmed with scanning electron microscopy. The theoretical analysis revealed that the coexistence of different anionic forms of the analyte in basic solution might lower the binding capacity of the MIP towards BPA. The release profiles from the model phosphate buffer saline showed that only 0 to 4.81% of BPA was released from the MIP within the time frame of two hours, furthermore, the obtained material was considered non-cytotoxic towards tested cell lines. The results prove that MIPs can be considered as effective BPA delivery systems for biomedical applications and should be investigated in further studies.
Collapse
Affiliation(s)
- Emilia Balcer
- Department of Drug Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
- Radiochemistry Team, Reactor Research Division, Nuclear Facilities Operations Department, National Centre for Nuclear Research, Sołtana 7, Świerk, 05-400 Otwock, Poland
| | - Monika Sobiech
- Department of Organic and Physical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
| | - Joanna Giebułtowicz
- Department of Drug Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
| | - Małgorzata Sochacka
- Department of Drug Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
| | - Piotr Luliński
- Department of Organic and Physical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
| |
Collapse
|
19
|
Fukumura M, Nonoguchi N, Kawabata S, Hiramatsu R, Futamura G, Takeuchi K, Kanemitsu T, Takata T, Tanaka H, Suzuki M, Sampetrean O, Ikeda N, Kuroiwa T, Saya H, Nakano I, Wanibuchi M. 5-Aminolevulinic acid increases boronophenylalanine uptake into glioma stem cells and may sensitize malignant glioma to boron neutron capture therapy. Sci Rep 2023; 13:10173. [PMID: 37349515 PMCID: PMC10287723 DOI: 10.1038/s41598-023-37296-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Accepted: 06/19/2023] [Indexed: 06/24/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a high-LET particle radiotherapy clinically tested for treating malignant gliomas. Boronophenylalanine (BPA), a boron-containing phenylalanine derivative, is selectively transported into tumor cells by amino acid transporters, making it an ideal agent for BNCT. In this study, we investigated whether the amino acid 5-aminolevulinic acid (ALA) could sensitize glioma stem cells (GSCs) to BNCT by enhancing the uptake of BPA. Using human and mouse GSC lines, pre-incubation with ALA increased the intracellular accumulation of BPA dose-dependent. We also conducted in vivo experiments by intracerebrally implanting HGG13 cells in mice and administering ALA orally 24 h before BPA administration (ALA + BPA-BNCT). The ALA preloading group increased the tumor boron concentration and improved the tumor/blood boron concentration ratio, resulting in improved survival compared to the BPA-BNCT group. Furthermore, we found that the expression of amino acid transporters was upregulated following ALA treatment both in vitro and in vivo, particularly for ATB0,+. This suggests that ALA may sensitize GSCs to BNCT by upregulating the expression of amino acid transporters, thereby enhancing the uptake of BPA and improving the effectiveness of BNCT. These findings have important implications for strategies to improve the sensitivity of malignant gliomas to BPA-BNCT.
Collapse
Affiliation(s)
- Masao Fukumura
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-8686, Japan
| | - Naosuke Nonoguchi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-8686, Japan.
| | - Shinji Kawabata
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-8686, Japan
| | - Ryo Hiramatsu
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-8686, Japan
| | - Gen Futamura
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-8686, Japan
| | - Koji Takeuchi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-8686, Japan
| | - Takuya Kanemitsu
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-8686, Japan
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori, Osaka, Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori, Osaka, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori, Osaka, Japan
| | - Oltea Sampetrean
- Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
| | - Naokado Ikeda
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-8686, Japan
| | - Toshihiko Kuroiwa
- Department of Neurosurgery, Tesseikai Neurosurgical Hospital, Shijonawate, Osaka, Japan
| | - Hideyuki Saya
- Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
| | - Ichiro Nakano
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Masahiko Wanibuchi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-8686, Japan
| |
Collapse
|
20
|
Oloo SO, Smith KM, Vicente MDGH. Multi-Functional Boron-Delivery Agents for Boron Neutron Capture Therapy of Cancers. Cancers (Basel) 2023; 15:3277. [PMID: 37444386 DOI: 10.3390/cancers15133277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 06/03/2023] [Accepted: 06/19/2023] [Indexed: 07/15/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a binary cancer treatment that involves the irradiation of 10B-containing tumors with low-energy neutrons (thermal or epithermal). The alpha particles and recoiling Li nuclei that are produced in the 10B-capture nuclear reaction are high-linear-energy transfer particles that destroy boron-loaded tumor cells; therefore, BNCT has the potential to be a localized therapeutic modality. Two boron-delivery agents have been used in clinical trials of BNCT in patients with malignant brain tumors, cutaneous melanoma, or recurrent tumors of the head and neck region, demonstrating the potential of BNCT in the treatment of difficult cancers. A variety of potentially highly effective boron-delivery agents have been synthesized in the past four decades and tested in cells and animal models. These include boron-containing nucleosides, peptides, proteins, polyamines, porphyrins, liposomes, monoclonal antibodies, and nanoparticles of various types. The most promising agents are multi-functional boronated molecules and nanoparticles functionalized with tumor cell-targeting moieties that increase their tumor selectivity and contain a radiolabel or fluorophore to allow quantification of 10B-biodistribution and treatment planning. This review discusses multi-functional boron agents reported in the last decade, but their full potential can only be ascertained after their evaluation in BNCT clinical trials.
Collapse
Affiliation(s)
- Sebastian O Oloo
- Department of Chemistry, Louisiana State University, Baton Rouge, LA 70803, USA
| | - Kevin M Smith
- Department of Chemistry, Louisiana State University, Baton Rouge, LA 70803, USA
| | | |
Collapse
|
21
|
Zhou Z, Guan B, Xia H, Zheng R, Xu B. Particle radiotherapy in the era of radioimmunotherapy. Cancer Lett 2023:216268. [PMID: 37331583 DOI: 10.1016/j.canlet.2023.216268] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 05/24/2023] [Accepted: 06/11/2023] [Indexed: 06/20/2023]
Abstract
Radiotherapy (RT) is one of the key modalities for cancer treatment, and more than 70% of tumor patients will receive RT during the course of their disease. Particle radiotherapy, such as proton radiotherapy, carbon-ion radiotherapy (CIRT) and boron neutron capture therapy (BNCT), is currently available for the treatment of patients Immunotherapy combined with photon RT has been successfully used in the clinic. The effect of immunotherapy combined with particle RT is an area of interest. However, the molecular mechanisms underlying the effects of combined immunotherapy and particle RT remain largely unknown. In this review, we summarize the properties of different types of particle RT and the mechanisms underlying their radiobiological effects. Additionally, we compared the main molecular players in photon RT and particle RT and the mechanisms involved the RT-mediated immune response.
Collapse
Affiliation(s)
- Zihan Zhou
- Department of Radiation Oncology, Fujian Medical University Union Hospital, Xinquan Road 29, Fuzhou, 350000, Fuzhou, China.
| | - Bingjie Guan
- Department of Radiation Oncology, Fujian Medical University Union Hospital, Xinquan Road 29, Fuzhou, 350000, Fuzhou, China.
| | - Huang Xia
- Department of Radiation Oncology, Fujian Medical University Union Hospital, Xinquan Road 29, Fuzhou, 350000, Fuzhou, China.
| | - Rong Zheng
- Department of Radiation Oncology, Fujian Medical University Union Hospital, Xinquan Road 29, Fuzhou, 350000, Fuzhou, China; Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors (Fujian Medical University), Fuzhou, Xinquan Road 29, Fuzhou, 350000, Fujian, China; Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive, Hematological and Breast Malignancies), Fuzhou, Xinquan Road 29, Fuzhou, 350000, Fujian, China.
| | - Benhua Xu
- Department of Radiation Oncology, Fujian Medical University Union Hospital, Xinquan Road 29, Fuzhou, 350000, Fuzhou, China; Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors (Fujian Medical University), Fuzhou, Xinquan Road 29, Fuzhou, 350000, Fujian, China; Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive, Hematological and Breast Malignancies), Fuzhou, Xinquan Road 29, Fuzhou, 350000, Fujian, China.
| |
Collapse
|
22
|
Hleli B, Medoš Ž, Ogrin P, Tošner Z, Kereïche S, Gradzielski M, Urbič T, Bešter-Rogač M, Matějíček P. Closo-dodecaborate-based dianionic surfactants with distorted classical morphology: Synthesis and atypical micellization in water. J Colloid Interface Sci 2023; 648:809-819. [PMID: 37327624 DOI: 10.1016/j.jcis.2023.06.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2023] [Revised: 05/18/2023] [Accepted: 06/04/2023] [Indexed: 06/18/2023]
Abstract
HYPOTHESIS To challenge the classical concept of step-like micellization of ionic surfactants with singular critical micelle concentration, novel amphiphilic compounds with bulky dianionic head and the alkoxy tail connected via short linker, which can complex sodium cations, were synthesized in the form of disodium salts. EXPERIMENT The surfactants were synthesized by opening of a dioxanate ring attached to closo-dodecaborate by activated alcohol, which allows for attachment of alkyloxy tails of desired length to boron cluster dianion. The synthesis of the compounds with high cationic purity (sodium salt) is described. Self-assembly of the surfactant compound at air/water interface and in bulk water was studied by tensiometry, light and small angle X-ray scattering, electron microscopy, NMR spectroscopy, MD simulations and by isothermal titration calorimetry, ITC. The peculiarities in the micelle structure and formation were revealed by thermodynamic modelling and MD simulations of the micellization process. FINDINGS In an atypical process, the surfactants self-assemble in water to form relatively small micelles, where the aggregation number is decreasing with the surfactant concentration. The extensive counterion binding is a key characteristic of the micelles. The analysis strongly indicates complex compensation between the degree of bound sodium ions and the aggregation number. For the first time, a three-step thermodynamic model was used to estimate the thermodynamic parameters associated with micellization process. Diverse micelles differing in size and counterion binding can (co-)exist in the solution over the broad concentration and temperature range. Thus, the concept of step-like micellization was found inappropriate for these types of micelles.
Collapse
Affiliation(s)
- Belhssen Hleli
- Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University, Hlavova 2030/8, 128 40 Prague 2, Czech Republic
| | - Žiga Medoš
- Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, SI-1000 Ljubljana, Slovenia
| | - Peter Ogrin
- Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, SI-1000 Ljubljana, Slovenia
| | - Zdeněk Tošner
- NMR Laboratory, Faculty of Science, Charles University, Hlavova 2030/8, 128 40 Prague 2, Czech Republic
| | - Sami Kereïche
- Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, 128 000 Prague 2, Czech Republic
| | - Michael Gradzielski
- Stranski-Laboratorium für Physikalische Chemie und Theoretische Chemie, Institut für Chemie Sekr. TC 7, Technische Universität Berlin, Strasse des 17. Juni 124, D-10623 Berlin, Germany
| | - Tomaž Urbič
- Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, SI-1000 Ljubljana, Slovenia
| | - Marija Bešter-Rogač
- Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, SI-1000 Ljubljana, Slovenia.
| | - Pavel Matějíček
- Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University, Hlavova 2030/8, 128 40 Prague 2, Czech Republic.
| |
Collapse
|
23
|
Wang K, Ma L, Yang C, Bian Z, Zhang D, Cui S, Wang M, Chen Z, Li X. Recent Progress in Gd-Containing Materials for Neutron Shielding Applications: A Review. MATERIALS (BASEL, SWITZERLAND) 2023; 16:4305. [PMID: 37374489 DOI: 10.3390/ma16124305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Revised: 06/05/2023] [Accepted: 06/08/2023] [Indexed: 06/29/2023]
Abstract
With the rising demand for nuclear energy, the storage/transportation of radioactive nuclear by-products are critical safety issues for humans and the environment. These by-products are closely related to various nuclear radiations. In particular, neutron radiation requires specific protection by neutron shielding materials due to its high penetrating ability to cause irradiation damage. Herein, a basic overview of neutron shielding is presented. Since gadolinium (Gd) has the largest thermal neutron capture cross-section among various neutron absorbing elements, it is an ideal neutron absorber for shielding applications. In the last two decades, there have been many newly developed Gd-containing (i.e., inorganic nonmetallic-based, polymer-based, and metallic-based) shielding materials developed to attenuate and absorb the incident neutrons. On this basis, we present a comprehensive review of the design, processing methods, microstructure characteristics, mechanical properties, and neutron shielding performance of these materials in each category. Furthermore, current challenges for the development and application of shielding materials are discussed. Finally, the potential research directions are highlighted in this rapidly developing field.
Collapse
Affiliation(s)
- Kangbao Wang
- School of Materials Science and Engineering, Shanghai Jiao Tong University, Shanghai 200240, China
- State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University, Shanghai 200240, China
| | - Litao Ma
- School of Materials Science and Engineering, Shanghai Jiao Tong University, Shanghai 200240, China
- State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University, Shanghai 200240, China
| | - Chen Yang
- School of Materials Science and Engineering, Shanghai Jiao Tong University, Shanghai 200240, China
- State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University, Shanghai 200240, China
| | - Zeyu Bian
- Innovation Academy for Microsatellites of Chinese Academy of Sciences, Shanghai 201203, China
| | - Dongdong Zhang
- Innovation Academy for Microsatellites of Chinese Academy of Sciences, Shanghai 201203, China
| | - Shuai Cui
- Innovation Academy for Microsatellites of Chinese Academy of Sciences, Shanghai 201203, China
| | - Mingliang Wang
- School of Materials Science and Engineering, Shanghai Jiao Tong University, Shanghai 200240, China
- School of Physics and Lectronic Information College, Huaibei Normal University, Huaibei 235000, China
- Institute of Alumics Materials, Shanghai Jiao Tong University (Anhui), Huaibei 235000, China
| | - Zhe Chen
- State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University, Shanghai 200240, China
- Institute of Alumics Materials, Shanghai Jiao Tong University (Anhui), Huaibei 235000, China
| | - Xianfeng Li
- School of Materials Science and Engineering, Shanghai Jiao Tong University, Shanghai 200240, China
- School of Physics and Lectronic Information College, Huaibei Normal University, Huaibei 235000, China
| |
Collapse
|
24
|
Xiang J, Ma L, Tong J, Zuo N, Hu W, Luo Y, Liu J, Liang T, Ren Q, Liu Q. Boron-peptide conjugates with angiopep-2 for boron neutron capture therapy. Front Med (Lausanne) 2023; 10:1199881. [PMID: 37324130 PMCID: PMC10267362 DOI: 10.3389/fmed.2023.1199881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 05/15/2023] [Indexed: 06/17/2023] Open
Abstract
Boron neutron capture therapy (BNCT) induces intracellular nuclear reaction to destroy cancer cells during thermal neutron irradiation. To selectively eliminate cancer cells but avoid harmful effects on normal tissues, novel boron-peptide conjugates with angiopep-2, namely ANG-B, were constructed and evaluated in preclinical settings. Boron-peptide conjugates were synthesized using solid-phase peptide synthesis, and the molecular mass was validated by mass spectrometry afterwards. Boron concentrations in 6 cancer cell lines and an intracranial glioma mouse model after treatments were analyzed by inductively coupled plasma atomic emission spectroscopy (ICP-AES). Phenylalanine (BPA) was tested in parallel for comparison. In vitro treatment with boron delivery peptides significantly increased boron uptake in cancer cells. BNCT with 5 mM ANG-B caused 86.5% ± 5.3% of clonogenic cell death, while BPA at the same concentration caused 73.3% ± 6.0% clonogenic cell death. The in vivo effect of ANG-B in an intracranial glioma mouse model was evaluated by PET/CT imaging at 31 days after BNCT. The mouse glioma tumours in the ANG-B-treated group were shrunk by 62.9% on average, while the BPA-treated tumours shrank by only 23.0%. Therefore, ANG-B is an efficient boron delivery agent, which has low cytotoxicity and high tumour-to-blood ratio. Based on these experimental results, we expected that ANG-B may leverage BNCT performance in clinical applications in future.
Collapse
Affiliation(s)
- Jing Xiang
- Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Shenzhen, China
| | - Lin Ma
- Department of Stomatology, General Hospital, Shenzhen University, Shenzhen, Guangdong, China
| | - Jianfei Tong
- Institute of High Energy Physics, Chinese Academy of Sciences (CAS), Beijing, China
- Spallation Neutron Source Science Center, Dongguan, China
| | - Nan Zuo
- Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, Guangdong, China
- Department of Stomatology, The First Hospital, Harbin Medical University, Harbin, China
| | - Weitao Hu
- School of Stomatology, Hangzhou Normal University, Hangzhou, Zhejiang, China
| | - Yupeng Luo
- School of Stomatology, Shenzhen University, Shenzhen, Guangdong, China
| | - Junqi Liu
- Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Tianjiao Liang
- Institute of High Energy Physics, Chinese Academy of Sciences (CAS), Beijing, China
- Spallation Neutron Source Science Center, Dongguan, China
| | - Qiushi Ren
- Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Shenzhen, China
- Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, Guangdong, China
| | - Qi Liu
- Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, Guangdong, China
- International Cancer Center, Shenzhen University School of Medicine, Shenzhen University, Shenzhen, Guangdong, China
| |
Collapse
|
25
|
Seneviratne DS, Saifi O, Mackeyev Y, Malouff T, Krishnan S. Next-Generation Boron Drugs and Rational Translational Studies Driving the Revival of BNCT. Cells 2023; 12:1398. [PMID: 37408232 DOI: 10.3390/cells12101398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 04/26/2023] [Accepted: 05/04/2023] [Indexed: 07/07/2023] Open
Abstract
BNCT is a high-linear-energy transfer therapy that facilitates tumor-directed radiation delivery while largely sparing adjacent normal tissues through the biological targeting of boron compounds to tumor cells. Tumor-specific accumulation of boron with limited accretion in normal cells is the crux of successful BNCT delivery. Given this, developing novel boronated compounds with high selectivity, ease of delivery, and large boron payloads remains an area of active investigation. Furthermore, there is growing interest in exploring the immunogenic potential of BNCT. In this review, we discuss the basic radiobiological and physical aspects of BNCT, traditional and next-generation boron compounds, as well as translational studies exploring the clinical applicability of BNCT. Additionally, we delve into the immunomodulatory potential of BNCT in the era of novel boron agents and examine innovative avenues for exploiting the immunogenicity of BNCT to improve outcomes in difficult-to-treat malignancies.
Collapse
Affiliation(s)
| | - Omran Saifi
- Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA
| | - Yuri Mackeyev
- Department of Neurosurgery, UTHealth, Houston, TX 77030, USA
| | - Timothy Malouff
- Department of Radiation Oncology, University of Oklahoma, Oklahoma City, OK 73019, USA
| | - Sunil Krishnan
- Department of Neurosurgery, UTHealth, Houston, TX 77030, USA
| |
Collapse
|
26
|
Matović J, Bahrami K, Stockmann P, Sokka IK, Khng YC, Sarparanta M, Hey-Hawkins E, Rautio J, Ekholm FS. Sweet Battle of the Epimers─Continued Exploration of Monosaccharide-Derived Delivery Agents for Boron Neutron Capture Therapy. Mol Pharm 2023. [PMID: 37134022 DOI: 10.1021/acs.molpharmaceut.3c00119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
Boron neutron capture therapy (BNCT) is a cancer therapy in which boron delivery agents play a crucial role. In theory, delivery agents with high tumor targeting capabilities can lead to selective eradication of tumor cells without causing harmful side effects. We have been working on a GLUT1-targeting strategy to BNCT for a number of years and found multiple promising hit compounds which outperform the clinically employed boron delivery agents in vitro. Herein, we continue our work in the field by further diversification of the carbohydrate scaffold in order to map the optimal stereochemistry of the carbohydrate core. In the sweet battle of the epimers, carborane-bearing d-galactose, d-mannose, and d-allose are synthesized and subjected to in vitro profiling studies─with earlier work on d-glucose serving as the reference. We find that all of the monosaccharide delivery agents display a significantly improved boron delivery capacity over the delivery agents approved for clinical use in vitro, thus providing a sound foundation for advancing toward in vivo preclinical assessment studies.
Collapse
Affiliation(s)
- Jelena Matović
- Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, Helsinki FI-00014, Finland
| | - Katayun Bahrami
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, Kuopio FI-70211, Finland
| | - Philipp Stockmann
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Leipzig University, Leipzig D-04103, Germany
| | - Iris K Sokka
- Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, Helsinki FI-00014, Finland
| | - You Cheng Khng
- Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, Helsinki FI-00014, Finland
| | - Mirkka Sarparanta
- Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, Helsinki FI-00014, Finland
| | - Evamarie Hey-Hawkins
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Leipzig University, Leipzig D-04103, Germany
| | - Jarkko Rautio
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, Kuopio FI-70211, Finland
| | - Filip S Ekholm
- Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, Helsinki FI-00014, Finland
| |
Collapse
|
27
|
Li H, Qiao W, Shen Y, Xu H, Fan Y, Liu Y, Lan Y, Gong Y, Chen F, Feng S. Biomimetic Boron Nitride Nanoparticles for Targeted Drug Delivery and Enhanced Antitumor Activity. Pharmaceutics 2023; 15:pharmaceutics15041269. [PMID: 37111754 PMCID: PMC10145272 DOI: 10.3390/pharmaceutics15041269] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Revised: 04/05/2023] [Accepted: 04/17/2023] [Indexed: 04/29/2023] Open
Abstract
Boron nitride nanomaterials are being increasingly recognized as vehicles for cancer drug delivery that increase drug loading and control drug release because of their excellent physicochemical properties and biocompatibility. However, these nanoparticles are often cleared rapidly by the immune system and have poor tumor targeting effects. As a result, biomimetic nanotechnology has emerged to address these challenges in recent times. Cell-derived biomimetic carriers have the characteristics of good biocompatibility, long circulation time, and strong targeting ability. Here, we report a biomimetic nanoplatform (CM@BN/DOX) prepared by encapsulating boron nitride nanoparticles (BN) and doxorubicin (DOX) together using cancer cell membrane (CCM) for targeted drug delivery and tumor therapy. The CM@BN/DOX nanoparticles (NPs) were able to target cancer cells of the same type on its own initiative through homologous targeting of cancer cell membranes. This led to a remarkable increase in cellular uptake. In vitro simulation of an acidic tumor microenvironment could effectively promote drug release from CM@BN/DOX. Furthermore, the CM@BN/DOX complex exhibited an excellent inhibitory effect against homotypic cancer cells. These findings suggest that CM@BN/DOX are promising in targeted drug delivery and potentially personalized therapy against their homologous tumor.
Collapse
Affiliation(s)
- Hui Li
- School of Environmental and Chemical Engineering, Shanghai University, 333 Nanchen Road, Shanghai 200444, China
- School of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China
| | - Wei Qiao
- School of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China
| | - Yizhe Shen
- School of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China
| | - Huashan Xu
- School of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China
| | - Yuan Fan
- School of Environmental and Chemical Engineering, Shanghai University, 333 Nanchen Road, Shanghai 200444, China
- School of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China
| | - Yuxiang Liu
- School of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China
| | - Yadi Lan
- School of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China
| | - Yan Gong
- School of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China
| | - Fuxue Chen
- School of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China
| | - Shini Feng
- School of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China
| |
Collapse
|
28
|
Vakhrushev AV, Gruzdev DA, Demin AM, Levit GL, Krasnov VP. Synthesis of Novel Carborane-Containing Derivatives of RGD Peptide. Molecules 2023; 28:molecules28083467. [PMID: 37110700 PMCID: PMC10143838 DOI: 10.3390/molecules28083467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 04/07/2023] [Accepted: 04/12/2023] [Indexed: 04/29/2023] Open
Abstract
Short peptides containing the Arg-Gly-Asp (RGD) fragment can selectively bind to integrins on the surface of tumor cells and are attractive transport molecules for the targeted delivery of therapeutic and diagnostic agents to tumors (for example, glioblastoma). We have demonstrated the possibility of obtaining the N- and C-protected RGD peptide containing 3-amino-closo-carborane and a glutaric acid residue as a linker fragment. The resulting carboranyl derivatives of the protected RGD peptide are of interest as starting compounds in the synthesis of unprotected or selectively protected peptides, as well as building blocks for preparation of boron-containing derivatives of the RGD peptide of a more complex structure.
Collapse
Affiliation(s)
- Alexander V Vakhrushev
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), 620108 Ekaterinburg, Russia
| | - Dmitry A Gruzdev
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), 620108 Ekaterinburg, Russia
| | - Alexander M Demin
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), 620108 Ekaterinburg, Russia
| | - Galina L Levit
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), 620108 Ekaterinburg, Russia
| | - Victor P Krasnov
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), 620108 Ekaterinburg, Russia
| |
Collapse
|
29
|
Terada S, Tsunetoh S, Tanaka Y, Tanaka T, Kashiwagi H, Takata T, Kawabata S, Suzuki M, Ohmichi M. Boron uptake of boronophenylalanine and the effect of boron neutron capture therapy in cervical cancer cells. Appl Radiat Isot 2023; 197:110792. [PMID: 37062147 DOI: 10.1016/j.apradiso.2023.110792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Revised: 06/13/2022] [Accepted: 03/26/2023] [Indexed: 04/05/2023]
Abstract
There are few studies about boron neutron capture therapy (BNCT) for cervical cancer. The present study evaluated the biodistribution of boronophenylalanine (BPA) and the effect of BNCT on cervical cancer cell lines. BPA exposure and neutron irradiation of cervical cancer cell lines resulted in decreased survival fraction compared to irradiation only. In vivo cervical cancer tumor boron concentration was highest at 2.5 h after BPA intraperitoneal administration, and higher than in the other organs. BNCT may be effective against cervical carcinoma.
Collapse
|
30
|
Matveev EY, Avdeeva VV, Kubasov AS, Zhizhin KY, Malinina EA, Kuznetsov NT. Synthesis and Structures of Lead(II) Complexes with Hydroxy-Substituted Closo-Decaborate Anions. INORGANICS 2023. [DOI: 10.3390/inorganics11040144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/31/2023] Open
Abstract
Mixed-ligand lead(II) complexes with 2,2′-bipyridyl and [B10H9OH]2− or monosubstituted hydroxy-substituted closo-decaborate anions with a pendant hydroxy group, separated from the boron cage by an alkoxylic spacer of different lengths [B10H9O(CH2)xO(CH2)2OH]]2− (x = 2 or 5) have been synthesized. Compounds have been characterized by IR and multinuclear NMR spectroscopies. The structures of binuclear complex [Pb(bipy)2[B10H9OH]]2·CH3CN (1·CH3CN), mononuclear complex [Pb(bipy)2[B10H9O(CH2)2O(CH2)2OH]]·0.5bipy·CH3CN (2·0.5bipy·CH3CN), and polymeric complex [Pb(bipy)[B10H9O(CH2)5O(CH2)2OH]]n (3) have been determined by single-crystal X-ray diffraction. In all three compounds, the co-ordination polyhedra of lead(II) are formed by N atoms from two bipy molecules, O atoms of the substituent attached to the boron cage, and BH groups of the boron cage.
Collapse
|
31
|
Masunaga SI, Sanada Y, Takata T, Tanaka H, Sakurai Y, Suzuki M, Kirihata M, Ono K. The impact of TP53 status of tumor cells including the type and the concentration of administered 10B delivery agents on compound biological effectiveness in boron neutron capture therapy. JOURNAL OF RADIATION RESEARCH 2023; 64:399-411. [PMID: 36763853 PMCID: PMC10036103 DOI: 10.1093/jrr/rrad001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Revised: 11/23/2022] [Indexed: 06/18/2023]
Abstract
Human head and neck squamous cell carcinoma cells transfected with mutant TP53 (SAS/mp53) or neo vector (SAS/neo) were inoculated subcutaneously into left hind legs of nude mice. After the subcutaneous administration of a 10B-carrier, boronophenylalanine-10B (BPA) or sodium mercaptododecaborate-10B (BSH), at two separate concentrations, the 10B concentrations in tumors were measured using γ-ray spectrometry. The tumor-bearing mice received 5-bromo-2'-deoxyuridine (BrdU) continuously to label all intratumor proliferating (P) tumor cells, then were administered with BPA or BSH. Subsequently, the tumors were irradiated with reactor neutron beams during the time of which 10B concentrations were kept at levels similar to each other. Following irradiation, cells from some tumors were isolated and incubated with a cytokinesis blocker. The responses of BrdU-unlabeled quiescent (Q) and total (= P + Q) tumor cells were assessed based on the frequencies of micronucleation using immunofluorescence staining for BrdU. In both SAS/neo and SAS/mp53 tumors, the compound biological effectiveness (CBE) values were higher in Q cells and in the use of BPA than total cells and BSH, respectively. The higher the administered concentrations were, the smaller the CBE values became, with a clearer tendency in SAS/neo tumors and the use of BPA than in SAS/mp53 tumors and BSH, respectively. The values for BPA that delivers into solid tumors more dependently on uptake capacity of tumor cells than BSH became more alterable. Tumor micro-environmental heterogeneity might partially influence on the CBE value. The CBE value can be regarded as one of the indices showing the level of intratumor heterogeneity.
Collapse
Affiliation(s)
- Shin-ichiro Masunaga
- Corresponding author. 1-1-48-4601, Fukushima, Fukushima-ku, Osaka, Osaka 553-0003, Japan. E-mail:
| | - Yu Sanada
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori, Osaka 590-0458, Japan
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori, Osaka 590-0458, Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori, Osaka 590-0458, Japan
| | - Yoshinori Sakurai
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori, Osaka 590-0458, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori, Osaka 590-0458, Japan
| | - Mitsunori Kirihata
- Research Center for Boron Neutron Capture Therapy, Osaka Metropolitan University, Sakai, Osaka, 599-8531, Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-0801, Japan
| |
Collapse
|
32
|
Sarkar M, Hey-Hawkins E, Boomishankar R. Encapsulation Studies on closo-Dicarbadodecaborane Isomers in Neutral Tetrahedral Palladium(II) Cages. Inorg Chem 2023; 62:4035-4042. [PMID: 36857772 DOI: 10.1021/acs.inorgchem.2c04207] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Abstract
The encapsulation of icosahedral closo-dicarbadodecaborane (o-, m-, and p-carboranes, Cb) as guest molecules at the intrinsic cavities of the three isostructural tetrahedral cages [{Pd3(NiPr)3PO}4(Cl-AN)6] (1), [{Pd3(NiPr)3PO}4(Br-AN)6] (2), and [{Pd3(NiPr)3PO}4(H-AN)6] (3) was studied. The formation of definite host-guest assemblies was probed with mass spectrometry, IR, and NMR spectral analysis. 2D DOSY 1H NMR of the Cb⊂Cage systems showed similar diffusion coefficient (D) values for the host and guest species, signifying the encapsulation of these guests inside the cage assemblies. The hydrodynamic radius (RH) derived from the D values of the host and guest species further confirmed the encapsulation of the Cb isomers at the cage pockets. The single-molecule energy optimization of the host-guest assemblies indicated the preferential binding of o-Cb as a guest inside the cages (1-3). The stabilization of these Cb guests inside these cages was further attributed to various possible nonclassical C-H···X-type interactions.
Collapse
Affiliation(s)
- Meghamala Sarkar
- Department of Chemistry, Indian Institute of Science Education and Research (IISER), Pune, Dr. Homi Bhabha Road, Pune 411008, India
| | - Evamarie Hey-Hawkins
- Institut für Anorganische Chemie, Fakultät für Chemie und Mineralogie, Universität Leipzig, Johannisallee 29, 04103 Leipzig, Germany
| | - Ramamoorthy Boomishankar
- Department of Chemistry, Indian Institute of Science Education and Research (IISER), Pune, Dr. Homi Bhabha Road, Pune 411008, India.,Centre for Energy Science, Indian Institute of Science Education and Research (IISER), Pune, Dr. Homi Bhabha Road, Pune 411008, India
| |
Collapse
|
33
|
Advances in Boron Neutron Capture Therapy (BNCT) for Recurrent Intracranial Meningioma. Int J Mol Sci 2023; 24:ijms24054978. [PMID: 36902408 PMCID: PMC10003570 DOI: 10.3390/ijms24054978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2023] [Revised: 02/20/2023] [Accepted: 03/02/2023] [Indexed: 03/08/2023] Open
Abstract
Meningiomas are the most frequently diagnosed primary intracranial tumors in adults. Surgical resection is preferred if the meningioma is accessible; for those that are not suitable for surgical resection, radiotherapy should be considered to improve local tumor control. However, recurrent meningiomas are challenging to treat, as the recurrent tumor might be located in the previously irradiated area. Boron Neutron Capture Therapy (BNCT) is a highly selective radiotherapy modality in which the cytotoxic effect focuses mainly on cells with increased uptake of boron-containing drugs. In this article, we describe four patients with recurrent meningiomas treated with BNCT in Taiwan. The mean boron-containing drug tumor-to-normal tissue uptake ratio was 4.125, and the tumor mean dose was 29.414 GyE, received via BNCT. The treatment response showed two stable diseases, one partial response, and one complete response. We also introduce and support the effectiveness and safety of BNCT as an alternative salvage treatment for recurrent meningiomas.
Collapse
|
34
|
Zhou Q, Liu H, Liu J, Liu Z, Xu C, Zhang H, Xin C. Screening Key Pathogenic Genes and Small Molecule Compounds for PNET. J Pediatr Hematol Oncol 2023; 45:e180-e187. [PMID: 36524840 PMCID: PMC9949520 DOI: 10.1097/mph.0000000000002605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Accepted: 11/04/2022] [Indexed: 12/23/2022]
Abstract
Primitive neuroectodermal tumors (PNET) are rare malignant tumors, but the mortality rate of the patients is extremely high. The aim of this study was to identify the hub genes and pathways involved in the pathogenesis of PNET and to screen the potential small molecule drugs for PNET. We extracted gene expression profiles from the Gene Expression Omnibus database and identified differentially expressed genes (DEGs) through Limma package in R. Two expression profiles (GSE14295 and GSE74195) were downloaded, including 33 and 5 cases separately. Four hundred sixty-eight DEGs (161 upregulated; 307 downregulated) were identified. Functional annotation and KEGG pathway enrichment of the DEGs were performed using DAVID and Kobas. Gene Ontology analysis showed the significantly enriched Gene Ontology terms included but not limited to mitosis, nuclear division, cytoskeleton, synaptic vesicle, syntaxin binding, and GABA A receptor activity. Cancer-related signaling pathways, such as DNA replication, cell cycle, and synaptic vesicle cycle, were found to be associated with these genes. Subsequently, the STRING database and Cytoscape were utilized to construct a protein-protein interaction and screen the hub genes, and we identified 5 hub genes (including CCNB1, CDC20, KIF11, KIF2C, and MAD2L1) as the key biomarkers for PNET. Finally, we identified potential small molecule drugs through CMap. Seven small molecule compounds, including trichostatin A, luteolin, repaglinide, clomipramine, lorglumide, vorinostat, and resveratrol may become potential candidates for PNET drugs.
Collapse
Affiliation(s)
- Qi Zhou
- Scientifific Research Management Office
| | - Hao Liu
- The second Hospital of Harbin, Harbin, Heilongjiang Proviance
| | - Junsi Liu
- Department of Neurosurgical laboratory
| | - Zhendong Liu
- Department of Orthopaedics, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou, Henan, China
| | - Caixia Xu
- Department of Neurosurgical laboratory
| | - Haiyu Zhang
- Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin Heilongjiang Province
| | - Chen Xin
- Department of Neurosurgical laboratory
| |
Collapse
|
35
|
Moktan H, Lee CL, Cho SH. Prompt gamma ray detection and imaging for boron neutron capture therapy using CdTe detector and novel detector shield - Monte Carlo study. Med Phys 2023; 50:1736-1745. [PMID: 36625477 DOI: 10.1002/mp.16207] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 11/21/2022] [Accepted: 12/19/2022] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND For boron neutron capture therapy (BNCT), the improvements in patient dosimetry will require information about the spatial variation of 10 B concentration in the tumor and critical organs. A non-invasive approach, based on the detection of prompt gamma (PG) rays from the BNC reaction, may be well-suited to obtain such information. The detectability of the BNC PG rays has been shown experimentally utilizing energy-resolving cadmium telluride (CdTe) detectors. However, the feasibility of this approach under the clinically relevant conditions of BNCT is currently unknown. PURPOSE The present work aimed to investigate the aforementioned feasibility by performing Monte Carlo (MC) simulations under the phantom irradiation geometry relevant to accelerator-based BNCT (a-BNCT). Especially, this investigation focused on demonstrating the enhanced detection of the BNC PG rays using a novel neutron shield for CdTe detectors. Upon demonstrating the efficacy of the proposed detector shield, the BNC PG ray-based quantitative imaging of clinically relevant concentrations of 10 B was also demonstrated. METHODS The Geant4 MC simulation toolkit was used to model the phantom irradiation by an epithermal neutron beam as well as the detection of the BNC PG rays from the phantom by CdTe detectors with and without the proposed gadolinium (Gd)-based detector shield. It was also used to model the BNC PG ray-based quantitative imaging of 10 B concentrations under a-BNCT scenarios. Each model included a 20 cm-diameter/24 cm-height cylindrical PMMA phantom containing 10 B inserts at various concentrations. Arrays of CdTe crystals of 5 × 5 × 1 mm3 each (up to 120 in the case of a ring detector) were modeled for acquiring the BNC PG ray signals and quantitative imaging. RESULTS According to the MC simulations, thermalized neutrons from the phantom were found to reach the CdTe detector and captured by Cd and Te, resulting in the gamma ray background noise that directly interfered with the BNC PG ray signal. The proposed Gd-based detector shield was found to be highly effective in shielding thermal neutrons from the phantom, thereby reducing the unwanted gamma ray background noise. Owing to this shield, the detection of as low as seven parts-per-million (ppm) of 10 B within the phantom of clinically relevant size was possible using 20 billion incident neutron histories. Furthermore, quantitative imaging of 10 B distributed at low concentration (down to 50 ppm) within the phantom was demonstrated using computed tomography (CT) simulations with 16 billion incident neutron histories per angular projection. The 10 B detection limit (7.5 ppm) was also estimated using the reconstructed CT image. Both 10 B detection limits determined from this investigation are deemed clinically relevant for BNCT. CONCLUSIONS The proposed Gd-based detector shield played an essential role for achieving the currently reported 10 B detection limits. Overall, the present MC simulation work demonstrated highly sensitive BNC PG ray detection and imaging under a-BNCT scenarios using CdTe detectors coupled with a novel detector shield.
Collapse
Affiliation(s)
- Hem Moktan
- Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Chad L Lee
- TAE Life Sciences, Foothill Ranch, California, USA
| | - Sang Hyun Cho
- Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
- Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
36
|
Improved Boron Neutron Capture Therapy Using Integrin αvβ3-Targeted Long-Retention-Type Boron Carrier in a F98 Rat Glioma Model. BIOLOGY 2023; 12:biology12030377. [PMID: 36979069 PMCID: PMC10045558 DOI: 10.3390/biology12030377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 02/24/2023] [Accepted: 02/25/2023] [Indexed: 03/03/2023]
Abstract
Integrin αvβ3 is more highly expressed in high-grade glioma cells than in normal tissues. In this study, a novel boron-10 carrier containing maleimide-functionalized closo-dodecaborate (MID), serum albumin as a drug delivery system, and cyclic arginine-glycine-aspartate (cRGD) that can target integrin αvβ3 was developed. The efficacy of boron neutron capture therapy (BNCT) targeting integrin αvβ3 in glioma cells in the brain of rats using a cRGD-functionalized MID-albumin conjugate (cRGD-MID-AC) was evaluated. F98 glioma cells exposed to boronophenylalanine (BPA), cRGD-MID-AC, and cRGD + MID were used for cellular uptake and neutron-irradiation experiments. An F98 glioma-bearing rat brain tumor model was used for biodistribution and neutron-irradiation experiments after BPA or cRGD-MID-AC administration. BNCT using cRGD-MID-AC had a sufficient cell-killing effect in vitro, similar to that with BNCT using BPA. In biodistribution experiments, cRGD-MID-AC accumulated in the brain tumor, with the highest boron concentration observed 8 h after administration. Significant differences were observed between the untreated group and BNCT using cRGD-MID-AC groups in the in vivo neutron-irradiation experiments through the log-rank test. Long-term survivors were observed only in BNCT using cRGD-MID-AC groups 8 h after intravenous administration. These findings suggest that BNCT with cRGD-MID-AC is highly selective against gliomas through a mechanism that is different from that of BNCT with BPA.
Collapse
|
37
|
Meher N, VanBrocklin HF, Wilson DM, Flavell RR. PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer. Pharmaceuticals (Basel) 2023; 16:315. [PMID: 37259457 PMCID: PMC9964110 DOI: 10.3390/ph16020315] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 02/11/2023] [Accepted: 02/12/2023] [Indexed: 08/26/2023] Open
Abstract
Targeted nanotheranostic systems offer significant benefits due to the integration of diagnostic and therapeutic functionality, promoting personalized medicine. In recent years, prostate-specific membrane antigen (PSMA) has emerged as an ideal theranostic target, fueling multiple new drug approvals and changing the standard of care in prostate cancer (PCa). PSMA-targeted nanosystems such as self-assembled nanoparticles (NPs), liposomal structures, water-soluble polymers, dendrimers, and other macromolecules are under development for PCa theranostics due to their multifunctional sensing and therapeutic capabilities. Herein, we discuss the significance and up-to-date development of "PSMA-targeted nanocarrier systems for radioligand imaging and therapy of PCa". The review also highlights critical parameters for designing nanostructured radiopharmaceuticals for PCa, including radionuclides and their chelators, PSMA-targeting ligands, and the EPR effect. Finally, prospects and potential for clinical translation is discussed.
Collapse
Affiliation(s)
- Niranjan Meher
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94143, USA
| | - Henry F. VanBrocklin
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94143, USA
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
| | - David M. Wilson
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94143, USA
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
| | - Robert R. Flavell
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94143, USA
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
- Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA
| |
Collapse
|
38
|
Wang S, Zhang Z, Miao L, Zhang J, Tang F, Teng M, Li Y. Construction of targeted 10B delivery agents and their uptake in gastric and pancreatic cancer cells. Front Oncol 2023; 13:1105472. [PMID: 36845737 PMCID: PMC9947830 DOI: 10.3389/fonc.2023.1105472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Accepted: 01/30/2023] [Indexed: 02/11/2023] Open
Abstract
Boron Neutron Capture Therapy (BNCT) is a new binary radiation therapy for tumor tissue, which kills tumor cells with neutron capture reaction. Boron neutron capture therapy has become a technical means for glioma, melanoma, and other diseases has been included in the clinical backup program. However, BNCT is faced with the key problem of developing and innovating more efficient boron delivery agents to solve the targeting and selectivity. We constructed a tyrosine kinase inhibitor-L-p-boronophenylalanine (TKI-BPA) molecule, aiming to improve the selectivity of boron delivery agents by conjugating targeted drugs while increasing the molecular solubility by adding hydrophilic groups. It shows excellent selectivity in differential uptake of cells, and its solubility is more than 6 times higher than BPA, leading to the saving of boron delivery agents. This modification method is effective for improving the efficiency of the boron delivery agent and is expected to become a potential alternative with high clinical application value.
Collapse
Affiliation(s)
- Song Wang
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China,Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China
| | - Zhengchao Zhang
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China,Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China
| | - Lele Miao
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China,Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China
| | - Jiaxing Zhang
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China,Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China
| | - Futian Tang
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China,Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China
| | - Muzhou Teng
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China,Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China,*Correspondence: Yumin Li, ; Muzhou Teng,
| | - Yumin Li
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China,Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China,*Correspondence: Yumin Li, ; Muzhou Teng,
| |
Collapse
|
39
|
Wang J, Steenhaut T, Li HW, Filinchuk Y. High Yield Autoclave Synthesis of pure M 2B 12H 12 (M = Na, K). Inorg Chem 2023; 62:2153-2160. [PMID: 36693191 DOI: 10.1021/acs.inorgchem.2c03810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Metal dodecaborates (MxB12H12) are a versatile class of materials used in polymer chemistry and cancer treatment and are promising candidates as electrolytes for solid-state batteries. However, a general and scalable approach has not yet been developed for producing high-purity B12H122- derivatives. In this work, we report a simple, efficient, and environmentally benign solvothermal method to prepare diffraction and 11B NMR pure Na2B12H12 (85% yield) and K2B12H12 (84% yield). This new synthetic approach is based on the use of the borane dimethyl sulfide complex (DMS·BH3) and borohydrides (NaBH4, KBH4) heated at different temperatures in diglyme in an autoclave. It was found that high-purity Na2B12H12·diglyme solvate is obtained via an intermediate formation of B3H8-, B9H14-, and B11H14-, which are all soluble in diglyme. Heating under vacuum is shown to be efficient for removing the coordinated diglyme, allowing the formation of unsolvated Na2B12H12. Autoclave synthesis starting from KBH4 directly yields solvent-free K2B12H12, and ball-milling KBH4 prior to the synthesis enabling us to significantly improve the final yield. The new synthetic method paves the way for large-scale synthesis of MxB12H12 derivatives, enabling to envisage a wider scope of practical applications.
Collapse
Affiliation(s)
- Jian Wang
- Institute of Condensed Matter and Nanosciences, Université Catholique de Louvain, 1348Louvain-la-Neuve, Belgium
| | - Timothy Steenhaut
- Institute of Condensed Matter and Nanosciences, Université Catholique de Louvain, 1348Louvain-la-Neuve, Belgium
| | - Hai-Wen Li
- Hefei General Machinery Research Institute, Hefei230031, China
| | - Yaroslav Filinchuk
- Institute of Condensed Matter and Nanosciences, Université Catholique de Louvain, 1348Louvain-la-Neuve, Belgium
| |
Collapse
|
40
|
Yang Q, Dai Q, Bao X, Zhou Y, Lu Y, Zhong H, Wu L, Guo Y, Liu L, Tan X, Xia Y, Han M, Wei Q. Evaluation of a Tumor-Targeting Oligosaccharide Nanosystem in BNCT on an Orthotopic Hepatocellular Carcinoma Model. Mol Pharm 2023; 20:1025-1038. [PMID: 36571795 DOI: 10.1021/acs.molpharmaceut.2c00771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Boron neutron capture therapy (BNCT) is becoming a promising radiation treatment technique dealing with tumors due to its cellular targeting specificity. In this article, based on the biocompatible chitosan oligosaccharide (COS), we designed a boron delivery system using carborane (CB) as a boron drug with cRGD peptide modification and paclitaxel (PTX) loaded in the hydrophobic core. The nanoparticles (cRGD-COS-CB/PTX) realized the boron delivery into tumor sites with an enhanced permeability and retention (EPR) effect and an active targeting effect achieved by the cRGD-integrin interaction on the surface of tumor cells. The uniform spherical nanoparticles can be selectively taken by hepatoma cells rather than normal hepatocytes. In vivo experiments showed that the nanoparticles had a targeting effect on tumor sites in both subcutaneous and orthotopic tumor models, which was an encouraging result for radiotherapy for liver cancer. To sum up, the nanoparticles we produced proved to be promising dual-functionalized nanoparticles for radiotherapy and chemotherapy.
Collapse
Affiliation(s)
- Qiyao Yang
- Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310058, China.,College of Pharmaceutical Sciences, Zhejiang University, Hangzhou310058, China
| | - Qi Dai
- Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310058, China
| | - Xiaoyan Bao
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou310058, China
| | - Yi Zhou
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou310058, China
| | - Yiying Lu
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou310058, China
| | - Haiqing Zhong
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou310058, China
| | - Linjie Wu
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou310058, China
| | - Yinglu Guo
- Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310058, China
| | - Lihong Liu
- Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310058, China
| | - Xin Tan
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou310058, China
| | - Yiyi Xia
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou310058, China
| | - Min Han
- Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310058, China.,College of Pharmaceutical Sciences, Zhejiang University, Hangzhou310058, China.,Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou310058, China
| | - Qichun Wei
- Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310058, China
| |
Collapse
|
41
|
Synthesis and Characterization of Gd-Functionalized B 4C Nanoparticles for BNCT Applications. Life (Basel) 2023; 13:life13020429. [PMID: 36836786 PMCID: PMC9967186 DOI: 10.3390/life13020429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2023] [Revised: 01/23/2023] [Accepted: 01/26/2023] [Indexed: 02/05/2023] Open
Abstract
Inorganic nanoparticles of boron-rich compounds represent an attractive alternative to boron-containing molecules, such as boronophenylalanine or boranes, for BNCT applications. This work describes the synthesis and biological activity of multifunctional boron carbide nanoparticles stabilized with polyacrylic acid (PAA) and a gadolinium (Gd)-rich solid phase. A fluorophore (DiI) was included in the PAA functionalization, allowing the confocal microscopy imaging of the nanoparticles. Analysis of the interaction and activity of these fluorescent Gd-containing B4C nanoparticles (FGdBNPs) with cultured cells was appraised using an innovative correlative microscopy approach combining intracellular neutron autoradiography, confocal, and SEM imaging. This new approach allows visualizing the cells, the FGdBNP, and the events deriving from the nuclear process in the same image. Quantification of 10B by neutron autoradiography in cells treated with FGdBNPs confirmed a significant accumulation of NPs with low levels of cellular toxicity. These results suggest that these NPs might represent a valuable tool for achieving a high boron concentration in tumoral cells.
Collapse
|
42
|
Watanabe T, Sanada Y, Hattori Y, Suzuki M. Correlation between the expression of LAT1 in cancer cells and the potential efficacy of boron neutron capture therapy. JOURNAL OF RADIATION RESEARCH 2023; 64:91-98. [PMID: 36371738 PMCID: PMC9855323 DOI: 10.1093/jrr/rrac077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Revised: 10/07/2022] [Indexed: 06/16/2023]
Abstract
Boron neutron capture therapy (BNCT) is a binary cancer therapy that involves boron administration and neutron irradiation. The nuclear reaction caused by the interaction of boron atom and neutron produces heavy particles with highly cytocidal effects and destruct tumor cells, which uptake the boron drug. p-Boronophenylalanine (BPA), an amino acid derivative, is used in BNCT. Tumor cells with increased nutrient requirements take up more BPA than normal tissues via the enhanced expression of LAT1, an amino acid transporter. The current study aimed to assess the correlation between the expression of LAT1 and the uptake capacity of BPA using genetically modified LAT1-deficient/enhanced cell lines. We conducted an in vitro study, SCC7 tumor cells wherein LAT1 expression was altered using CRISPR/Cas9 were used to assess BPA uptake capacity. Data from The Cancer Genome Atlas (TCGA) were used to examine the expression status of LAT1 in human tumor tissues, the potential impact of LAT1 expression on cancer prognosis and the potential cancer indications for BPA-based BNCT. We discovered that the strength of LAT1 expression strongly affected the BPA uptake ability of tumor cells. Among the histologic types, squamous cell carcinomas express high levels of LAT1 regardless of the primary tumor site. The higher LAT1 expression in tumors was associated with a higher expression of cell proliferation markers and poorer patient prognosis. Considering that BPA concentrate more in tumors with high LAT1 expression, the results suggest that BNCT is effective for cancers having poor prognosis with higher proliferative potential and nutritional requirements.
Collapse
Affiliation(s)
- Tsubasa Watanabe
- Corresponding author. Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494 Japan. Tel: +81-72-451-2407; Fax: +81-72-451-2627;
| | | | - Yoshihide Hattori
- Research Center for Boron Neutron Capture Therapy, Osaka Metropolitan University, 1-1 Gakuen-cho, Nakaku, Sakai, Osaka 599-8531, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan
| |
Collapse
|
43
|
Stem cell-nanomedicine system as a theranostic bio-gadolinium agent for targeted neutron capture cancer therapy. Nat Commun 2023; 14:285. [PMID: 36650171 PMCID: PMC9845336 DOI: 10.1038/s41467-023-35935-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Accepted: 01/09/2023] [Indexed: 01/19/2023] Open
Abstract
The potential clinical application of gadolinium-neutron capture therapy (Gd-NCT) for glioblastoma multiforme (GBM) treatment has been compromised by the fast clearance and nonspecific biodistribution of gadolinium-based agents. We have developed a stem cell-nanoparticle system (SNS) to actively target GBM for advanced Gd-NCT by magnetizing umbilical cord mesenchymal stem cells (UMSCs) using gadodiamide-concealed magnetic nanoparticles (Gd-FPFNP). Nanoformulated gadodiamide shielded by a dense surface composed of fucoidan and polyvinyl alcohol demonstrates enhanced cellular association and biocompatibility in UMSCs. The SNS preserves the ability of UMSCs to actively penetrate the blood brain barrier and home to GBM and, when magnetically navigates by an external magnetic field, an 8-fold increase in tumor-to-blood ratio is achieved compared with clinical data. In an orthotopic GBM-bearing rat model, using a single dose of irradiation and an ultra-low gadolinium dose (200 μg kg-1), SNS significantly attenuates GBM progression without inducing safety issues, prolonging median survival 2.5-fold compared to free gadodiamide. The SNS is a cell-based delivery system that integrates the strengths of cell therapy and nanotechnology, which provides an alternative strategy for the treatment of brain diseases.
Collapse
|
44
|
Recent Development of Radiofluorination of Boron Agents for Boron Neutron Capture Therapy of Tumor: Creation of 18F-Labeled C-F and B-F Linkages. Pharmaceuticals (Basel) 2023; 16:ph16010093. [PMID: 36678590 PMCID: PMC9866017 DOI: 10.3390/ph16010093] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 12/27/2022] [Accepted: 01/03/2023] [Indexed: 01/11/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a binary therapeutic technique employing a boron agent to be delivered to the tumor site followed by the irradiation of neutrons. Biofunctional molecules/nanoparticles labeled with F-18 can provide an initial pharmacokinetic profile of patients to guide the subsequent treatment planning procedure of BNCT. Borono phenylalanine (BPA), recognized by the l-type amino acid transporter, can cross the blood-brain barrier and be accumulated in gliomas. The radiofluoro BNCT agents are reviewed by considering (1) less cytotoxicity, (2) diagnosing and therapeutic purposes, (3) aqueous solubility and extraction route, as well as (4), the trifluoroborate effect. A trifluoroborate-containing amino acid such as fluoroboronotyrosine (FBY) represents an example with both functionalities of imaging and therapeutics. Comparing with the insignificant cytotoxicity of clinical BPA with IC50 > 500 μM, FBY also shows minute toxicity with IC50 > 500 μM. [18F]FBY is a potential diagnostic agent for its tumor to normal accumulation (T/N) ratio, which ranges from 2.3 to 24.5 from positron emission tomography, whereas the T/N ratio of FBPA is greater than 2.5. Additionally, in serving as a BNCT therapeutic agent, the boron concentration of FBY accumulated in gliomas remains uncertain. The solubility of 3-BPA is better than that of BPA, as evidenced by the cerebral dose of 3.4%ID/g vs. 2.2%ID/g, respectively. While the extraction route of d-BPA differs from that of BPA, an impressive T/N ratio of 6.9 vs. 1.5 is noted. [18F]FBPA, the most common clinical boron agent, facilitates the application of BPA in clinical BNCT. In addition to [18F]FBY, [18F] trifluoroborated nucleoside analog obtained through 1,3-dipolar cycloaddition shows marked tumoral uptake of 1.5%ID/g. Other examples using electrophilic and nucleophilic fluorination on the boron compounds are also reviewed, including diboronopinacolone phenylalanine and nonsteroidal anti-inflammatory agents.
Collapse
|
45
|
Mechetin GV, Zharkov DO. DNA Damage Response and Repair in Boron Neutron Capture Therapy. Genes (Basel) 2023; 14:127. [PMID: 36672868 PMCID: PMC9859301 DOI: 10.3390/genes14010127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2022] [Revised: 12/28/2022] [Accepted: 12/29/2022] [Indexed: 01/03/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is an approach to the radiotherapy of solid tumors that was first outlined in the 1930s but has attracted considerable attention recently with the advent of a new generation of neutron sources. In BNCT, tumor cells accumulate 10B atoms that react with epithermal neutrons, producing energetic α particles and 7Li atoms that damage the cell's genome. The damage inflicted by BNCT appears not to be easily repairable and is thus lethal for the cell; however, the molecular events underlying the action of BNCT remain largely unaddressed. In this review, the chemistry of DNA damage during BNCT is outlined, the major mechanisms of DNA break sensing and repair are summarized, and the specifics of the repair of BNCT-induced DNA lesions are discussed.
Collapse
Affiliation(s)
- Grigory V. Mechetin
- Department of Natural Sciences, Novosibirsk State University, 2 Pirogova St., 630090 Novosibirsk, Russia
- Siberian Branch of the Russian Academy of Sciences Institute of Chemical Biology and Fundamental Medicine, 8 Lavrentieva Ave., 630090 Novosibirsk, Russia
| | - Dmitry O. Zharkov
- Department of Natural Sciences, Novosibirsk State University, 2 Pirogova St., 630090 Novosibirsk, Russia
- Siberian Branch of the Russian Academy of Sciences Institute of Chemical Biology and Fundamental Medicine, 8 Lavrentieva Ave., 630090 Novosibirsk, Russia
| |
Collapse
|
46
|
Kukulin VI, Bibikov AV, Tkalya EV, Ceccarelli M, Bodrenko IV. 7Be and 22Na radionuclides for a new therapy for cancer. Biomol Concepts 2023; 14:bmc-2022-0028. [PMID: 38167297 DOI: 10.1515/bmc-2022-0028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Accepted: 04/18/2023] [Indexed: 01/05/2024] Open
Abstract
10B isotopes have been almost exclusively used in the neutron-capture radiation therapy (NCT) of cancer for decades. We have identified two other nuclides suitable for radiotherapy, which have ca. ten times larger cross section of absorption for neutrons and emit heavy charged particles. This would provide several key advantages for potential NCT, such as the possibility to use a lower nuclide concentration in the target tissues or a lower neutron irradiation flux. By detecting the characteristic γ radiation from the spontaneous decay of the radionuclides, one can image their biodistribution. These advantages could open up new possibilities for NCT applications as a safer and more efficient cancer therapy.
Collapse
Affiliation(s)
- Vladimir I Kukulin
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Leninskie gory, Moscow, Ru-119991, Russia
| | - Anton V Bibikov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Leninskie gory, Moscow, Ru-119991, Russia
| | - Eugene V Tkalya
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, 119991, 53 Leninskiy pr., Moscow, Russia
- Nuclear Safety Institute of RAS, Bol'shaya Tulskaya 52, Moscow, 115191, Russia
| | - Matteo Ceccarelli
- Department of Physics, University of Cagliari, S.P. Monserrato-Sestu km 0.700, I-09042 Monserrato (CA), Italy
- Istituto Officina dei Materiali, CNR-IOM Cagliari, Cittadella Universitaria, Monserrato (CA) 09042-I, Italy
| | - Igor V Bodrenko
- Istituto Officina dei Materiali, CNR-IOM Cagliari, Cittadella Universitaria, Monserrato (CA) 09042-I, Italy
- Ecole Normale Sup´erieure, D´epartement de Chimie - Laboratoire PASTEUR, 24 Rue Lhomond, 75005 Paris, France
| |
Collapse
|
47
|
Confalonieri L, Imperio D, Erhard A, Fallarini S, Compostella F, del Grosso E, Balcerzyk M, Panza L. Organotrifluoroborate Sugar Conjugates for a Guided Boron Neutron Capture Therapy: From Synthesis to Positron Emission Tomography. ACS OMEGA 2022; 7:48340-48348. [PMID: 36591151 PMCID: PMC9798496 DOI: 10.1021/acsomega.2c06551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Accepted: 11/29/2022] [Indexed: 06/17/2023]
Abstract
Sugars are a versatile tool for targeting malignant cells and have been extensively used for drug delivery and imaging techniques. Their prototype, fluorodeoxyglucose ([18F]FDG), is currently used for positron emission tomography. Boron neutron capture therapy (BNCT) is a cancer treatment that relies on irradiation with thermal neutrons of cancer cells previously loaded with [10B]-containing compounds. The recent introduction of accelerators as a neutron source for clinical use prompts the planning of delivery compounds enriched with boron able to be traced in real time. This work describes the first synthesis of a new class of sugar derivatives conjugated to a trifluoroborate moiety as potential theranostic agents. Stability and cytotoxicity studies are reported for all compounds, together with [18F] radiolabeling optimization and in vivo preliminary positron emission tomography (PET) experiments on a selected compound.
Collapse
Affiliation(s)
- Laura Confalonieri
- Department
of Pharmaceutical Sciences, University of
Eastern Piedmont Amedeo Avogadro, L.go Donegani 2/3, 28100 Novara, Italy
| | - Daniela Imperio
- Department
of Pharmaceutical Sciences, University of
Eastern Piedmont Amedeo Avogadro, L.go Donegani 2/3, 28100 Novara, Italy
| | - Alvaro Erhard
- Centro
Nacional de Aceleradores, Universidad de
Sevilla-CSIC-Junta de Andalucia, 41092 Sevilla, Spain
| | - Silvia Fallarini
- Department
of Pharmaceutical Sciences, University of
Eastern Piedmont Amedeo Avogadro, L.go Donegani 2/3, 28100 Novara, Italy
| | - Federica Compostella
- Department
of Medical Biotechnology and Translational Medicine, University of Milan, Via Saldini 50, 20133 Milano, Italy
| | - Erika del Grosso
- Department
of Pharmaceutical Sciences, University of
Eastern Piedmont Amedeo Avogadro, L.go Donegani 2/3, 28100 Novara, Italy
| | - Marcin Balcerzyk
- Centro
Nacional de Aceleradores, Universidad de
Sevilla-CSIC-Junta de Andalucia, 41092 Sevilla, Spain
- Departamento
de Fisiologia Medica y Biofisica, Universidad
de Sevilla, 41003 Sevilla, Spain
| | - Luigi Panza
- Department
of Pharmaceutical Sciences, University of
Eastern Piedmont Amedeo Avogadro, L.go Donegani 2/3, 28100 Novara, Italy
| |
Collapse
|
48
|
Wolfram A, Fuentes-Soriano P, Herold-Mende C, Romero-Nieto C. Boron- and phosphorus-containing molecular/nano platforms: exploiting pathological redox imbalance to fight cancer. NANOSCALE 2022; 14:17500-17513. [PMID: 36326151 DOI: 10.1039/d2nr03126d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Cancer is currently the second leading cause of death globally. Despite multidisciplinary efforts, therapies to fight various types of cancer still remain inefficient. Reducing high recurrence rates and mortality is thus a major challenge to tackle. In this context, redox imbalance is an undervalued characteristic of cancer. However, it may be targeted by boron- and phosphorus-containing materials to selectively or systemically fight cancer. In particular, boron and phosphorus derivatives are attractive building blocks for rational drug discovery due to their unique and wide regioselective chemistry, high degree of tuneability and chemical stability. Thus, they can be meticulously employed to access tunable molecular platforms to selectively exploit the redox imbalance of cancer cells towards necrosis/apoptosis. This field of research holds a remarkable potential; nevertheless, it is still in its infancy. In this mini-review, we underline recent advances in the development of boron- or phosphorus-derivatives as molecular/nano platforms for rational anticancer drug design. Our goal is to provide comprehensive information on different methodologies that bear an outstanding potential to further develop this very promising field of research.
Collapse
Affiliation(s)
- Anna Wolfram
- Faculty of Pharmacy, University of Castilla-La Mancha Calle Almansa 14 - Edif. Bioincubadora, 02008, Albacete, Spain.
| | - Pablo Fuentes-Soriano
- Faculty of Pharmacy, University of Castilla-La Mancha Calle Almansa 14 - Edif. Bioincubadora, 02008, Albacete, Spain.
| | - Christel Herold-Mende
- Division of Neurosurgical Research, Department of Neurosurgery, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
| | - Carlos Romero-Nieto
- Faculty of Pharmacy, University of Castilla-La Mancha Calle Almansa 14 - Edif. Bioincubadora, 02008, Albacete, Spain.
- Organisch-Chemisches Institut, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 270, 69120 Heidelberg, Germany
| |
Collapse
|
49
|
Uspenskii SA, Khaptakhanova PA. Boron nanoparticles in chemotherapy and radiotherapy: the synthesis, state-of-the-art, and prospects. Russ Chem Bull 2022. [DOI: 10.1007/s11172-022-3686-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
|
50
|
Matveev EY, Levitskaya VY, Novikov SS, Nichugovskii AI, Sokolov IE, Lukashevich SV, Kubasov AS, Zhizin KY, Kuznetsov NT. Synthesis and Study of Derivatives of the [B10H10]2– Anion with Primary Amines. RUSS J INORG CHEM+ 2022. [DOI: 10.1134/s0036023622601532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|